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Background-—Hospitalizations for acute myocardial infarctions (AMIs) are associated with changes in statin adherence. It is
unclear to what extent adherence changes, which patients are likely to change, and how post-discharge follow-up is associated
with statin adherence change.
Methods and Results-—This retrospective study used Medicare data for all fee-for-service beneficiaries 66 years and older with an
AMI hospitalization in 2008–2010 and statin use before their index AMI. Multivariable multinomial logistic regression models (odds
ratio [OR] and 99% confidence interval [CI]) were applied to assess associations between both patient characteristics and follow-up
with a primary care provider and/or cardiologist with the outcome of statin adherence change (increase or decrease) from the 6-
month pre- to 6-month post-AMI periods. Of 113 296 patients, 64.0% had no change in adherence, while 19.7% had increased and
16.3% had decreased adherence after AMI hospitalization. Black and Hispanic patients were more likely to have either increased or
decreased adherence than white patients. Patients who required coronary artery bypass graft surgery (OR, 1.34; 99% CI,
1.21–1.49) or percutaneous transluminal coronary angioplasty/stent procedure (OR, 1.25; 99% CI, 1.17–1.32) during their index
hospitalization were more likely to have increased adherence. Follow-up with a primary care provider was only mildly associated
with increased adherence (OR, 1.08; 99% CI, 1.00–1.16), while follow-up with a cardiologist (OR, 1.15; 99% CI, 1.05–1.25) or both
provider types (OR, 1.21; 99% CI, 1.12–1.30) had stronger associations with increased adherence.
Conclusions-—Post-AMI changes in statin adherence varied by patient characteristics, and improved adherence was associated
with post-discharge follow-up care, particularly with a cardiologist or both a primary care provider and a cardiologist. ( J Am Heart
Assoc. 2017;6:e007106. DOI: 10.1161/JAHA.117.007106.)
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A cute myocardial infarction (AMI) is a common cardio-vascular event with significant public health implica-
tions. Pharmacotherapy after an AMI, including the use of
statins, is a vital part of the secondary prevention treatment
strategy, and numerous studies have shown that patients
cannot experience the full benefit realized in clinical trials if
they are not adherent to these prescribed medications.1–4
Many patients older than 65 years are already taking statins
before an AMI, and it is unclear whether patients’ adherence
to statins may increase, decrease, or not change following an
AMI.
Interaction with healthcare providers may also affect a
patient’s response to a negative health event. However,
discontinuity during transitions in care––including both lack of
follow-up and breakdown of communication among multiple
providers––may also negatively impact adherence.5–7 It is
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unclear how post-AMI follow-up with either a primary care
provider (PCP) and/or a cardiologist may affect changes in
adherence among patients who are already using statins.8
In order to effectively develop clinical and policy
interventions to improve adherence to secondary prevention
therapies, it is important to understand how medication
adherence may change in response to an AMI, which
patients are more likely to have increased or decreased
adherence, and how follow-up with healthcare providers may
affect this change. The evidence available from prior studies
is insufficient to address these questions.8–11 Therefore, the
aims of this study were (1) to determine to what extent
older patients’ adherence to statins may change after an
AMI, (2) to identify patient characteristics associated with
change in statin adherence after an AMI, and (3) to assess
whether post-discharge follow-up with PCPs and/or cardiol-
ogists is associated with change in statin adherence after an
AMI.
Methods
Study Design, Data Sources, and Participants
This is a retrospective cohort study using the US Centers for
Medicare & Medicaid Services (CMS) Medicare Chronic
Conditions Data Warehouse (CCW) enrollment summary,
medical services, and prescription Part D event files from
2007 to 2011. We assembled a cohort of all Medicare fee-for-
service eligible beneficiaries who had an AMI from 2008 to
2010 (Figure 1). The eligibility criteria were (1) index AMI
hospitalization between January 1, 2008, and December 31,
2010; (2) age 66 years and older at the time of index
hospitalization; (3) survived hospitalization and discharged to
home/self-care; (4) continuous enrollment in Medicare Parts
A, B, and D for at least 12 months pre-hospital admission and
6 months post-hospital discharge or until death, whichever
occurred first; (5) filled at least one statin prescription in the
period between 360 and 14 days before index hospitalization;
and (6) did not have end-stage renal disease in the baseline
period. Index AMI hospitalization was identified using an
International Classification of Diseases, Ninth Revision (ICD-9),
code of 410.x1 in either the primary or secondary discharge
diagnosis field in the Medicare inpatient claims.12,13 If a
patient had multiple AMIs in the base year, only the first was
considered the index hospitalization. See Figure 2 for patient
selection and attrition based on eligibility criteria.
The study was approved by the institutional review board
of the University of North Carolina at Chapel Hill. Because this
was a secondary analysis of deidentified administrative claims
data, the need for informed consent was waived.
Statin Adherence and Adherence Change
Prescription claims for statins were identified in the prescrip-
tion Part D files. Adherence to statins was measured using the
proportion of days covered (PDC) (0–100%). Pre-AMI adher-
ence was measured in the 180 days before AMI hospital
admission; patients were left-censored if their first prescrip-
tion claim was identified during this time period. Post-AMI
adherence was measured for 180 days after discharge, but
patients were right-censored if they died within 6 months
after hospital discharge. The adherence measure was
adjusted for hospital stays and oversupply from previous
statin prescription fills. Patients were also categorized into
severely nonadherent (PDC <40%), moderately nonadherent
(PDC 40–79.9%), and adherent (PDC ≥80%); previous research
has shown a dose-response relationship with these statin
adherence categories and health outcomes.3
The outcome for this study was change in statin
adherence, a categorical variable defined with either 3 levels
or 5 levels (Figure 3). For the 3-level adherence change
outcome, change was defined as a “decrease” if the post-AMI
Clinical Perspective
What Is New?
• Follow-up with a clinician within 30 days of an acute
myocardial infarction (AMI) hospital discharge was associ-
ated with increased statin adherence among patients
already taking these medications pre-AMI.
• Follow-up with a cardiologist or both a cardiologist and a
primary care provider was more strongly associated with
increased adherence than follow-up with only a primary care
provider.
• Patients who required invasive procedures during AMI
hospitalization were more likely to have increased statin
adherence after AMI.
• The association of race/ethnicity with statin adherence
change was complex, with many black and Hispanic patients
being more likely to have decreases in adherence compared
with white patients.
What Are the Clinical Implications?
• Early follow-up with clinicians, especially cardiologists,
should be encouraged for patients after AMI to address
barriers to and the importance of medication adherence.
• Primary care providers should be aware of all post-AMI care
that patients are receiving. For patients who are unable to
follow up with a cardiologist, primary care providers should
place a strong emphasis on medication adherence and
consider innovative strategies to address barriers to adher-
ence.
• Patient sociodemographic characteristics, comorbidity bur-
den, and severity of the AMI hospitalization should all be
considered when counseling patients on medication adher-
ence.
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adherence was lower categorically than pre-AMI adherence,
an “increase” if the post-AMI adherence was higher categor-
ically, and “no change” if there was no movement from one
adherence category to another. For the 5-level adherence
change outcome, change was defined as a “major decrease” if
pre-AMI adherence was ≥80% and post-AMI adherence was
<40%, a “moderate decrease” for all other adherence
decreases, “no change,” a “major increase” if pre-AMI
adherence was <40% and post-AMI adherence was ≥80%,
and a “moderate increase” for all other adherence increases.
A continuous adherence change variable was calculated as
post-AMI PDC minus pre-AMI PDC, with values ranging from
100% to +100%.
Patient Characteristics
Sociodemographic data were ascertained from the enrollment
summary files. Characteristics measured included age at the
time of index hospital admission, sex, race/ethnicity, dual
eligibility in Medicare and Medicaid, and median household
income of the US Census block groups for individuals aged 65
years and older. Patients were identified as dually eligible for
Medicaid in the 3 months before AMI hospital admission.
Comorbidities and cardiovascular procedures were mea-
sured in the 12 months preceding the index AMI admission.
These variables included previous AMI, dementia/Alzheimer’s
disease, depression, ischemic heart disease, unstable angina,
lipid abnormalities, history of rhabdomyolysis/myopathy,
coronary artery bypass surgery (CABG), stent/percutaneous
transluminal coronary angioplasty (PTCA), and the Charlson
Comorbidity Index (CCI). Additionally, a modified CCI was
calculated that excluded AMI and dementia, as both variables
were included as separate variables in regression models.
Variables related to the index admission were measured
including type of AMI (subendocardial or transmural infarc-
tion), procedures (CABG, PTCA/stent, cardiac catheterization,
angiocardiography, infusion of platelet inhibitors, and infusion
of thrombolytics), complications (cardiogenic shock, cardiac
dysrhythmias, hypotension, acute renal failure, and heart
failure), length of index hospitalization, admission to an
intensive care unit or a coronary care unit, and a cardiologist
consultation during the admission. These patient character-
istics were measured using standardized algorithms from the
Chronic Conditions Data Warehouse14 and health services
research literature.15,16 Statin adherence in the pre-AMI
period was included as a predictor of adherence change.
Prescription claims for a b-blocker or angiotensin-converting
enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) in
the 6 months before the index admission were also identified.
Follow-Up With a Provider
Follow-up with a cardiologist or a PCP within 30 days after
hospital discharge was measured using outpatient and
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Figure 1. Study timeline. A, Index hospitalization (duration is length of stay). B, Twelve-month period used to identify baseline comorbidities.
This period was used to identify prevalent users of statins for study inclusion. C, Six-month period used to identify concurrent users of
angiotensin-converting (ACE) enzyme inhibitors/angiotensin receptor blockers (ARB) and b-blockers. Also used to measure pre–acute
myocardial infarction (AMI) statin adherence. If a patient’s first prescription claim occurred during this period, adherence was measured from the
date of that first fill until the first day of hospital admission for index AMI (0i,adm). D, Three-month period used to identify patients with dual
Medicare and Medicaid eligibility. If a patient had dual eligibility during any of these 3 months, they were considered dual eligible for the entire
study. E, Thirty-day period after index hospitalization discharge used to measure whether patient followed up with a primary care provider and/
or cardiologist. F, Follow-up period for all patients used to measure post-AMI statin adherence. This period lasted 6 months after hospital
discharge except for those individuals who died within 6 months of hospital discharge (n=12 281, 10.8%). Date of death was the end of follow-
up for these patients. 0i,dis indicates discharge date for index hospitalization (which was the beginning of the follow-up period for all patients).
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Figure 2. Patient attrition and eligibility criteria. AMI indicates acute myocardial infarction.
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physician office visit claims. Provider type was measured
using CMS Medicare Specialty Codes. PCPs included non-
specialist physicians, physician assistants, and nurse practi-
tioners as defined in clinical practice guidelines available
during the study period.17
Statistical Analysis
Distributions of patient sociodemographic and clinical char-
acteristics by categories of statin adherence change were
described. Absolute standardized differences were used to
assess unadjusted differences between groups stratified by
change in statin adherence.18 An absolute standardized
difference of ≥0.10 with “no change” as the reference group
was used as a cutoff to determine whether there were
significant differences in patient characteristics between
groups.19
Multivariable multinomial logistic regression models were
developed for the 3-level and 5-level categories of adherence
change with “no change” as the reference outcome group.
Multivariable regression models were utilized to identify
predictors of adherence change after an AMI in the domains
of sociodemographic characteristics, baseline clinical charac-
teristics, clinical events during index hospitalization, and
post-discharge follow-up. Adjusted odds ratios (ORs) with 99%
confidence intervals (CIs) were reported for all multinomial
logistic regression models.
We assessed the robustness and consistency of our model
estimates in 11 sensitivity analyses. First, using our full
sample, 5 additional sets of analyses were conducted: (1) to
alleviate the influence of small changes in adherence, a
categorical change in adherence also required an absolute
change of 10% in PDC to officially be defined as an adherence
change,8 (2) the period for post-AMI follow-up with clinicians
was extended to 42 days,20 (3) change in the simvastatin-
equivalent average daily dose from the pre- to post-AMI period
was added to a separate model,21,22 (4) categorical variables
indicating a high-, moderate-, or low-intensity statin for the
last fill before index AMI and first fill after index AMI were
added to a separate model,21 and (5) liver disease (a potential
contraindication for statins) was added to a separate model.
Second, we altered the cohort eligibility criteria in 3 separate
models: (6) patients must have had their first statin prescrip-
tion fill at least 6 months before index AMI, (7) patients must
have survived 6 months post-AMI discharge, and (8) patients
with another AMI within 6 months after discharge from their
index event were excluded. In addition, (9) adherence and
change in adherence were measured in the 12-month baseline
Figure 3. Definition of 3-level and 5-level categories of adherence change. AMI indicates acute
myocardial infarction; PDC, proportion of days covered; ref, reference.
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Table 1. Patient Characteristics Stratified by Change in Statin Adherence After AMI
Patient Characteristics
Total
Adherence Change
Decrease No Change Increase
N=113 296 n=18 502 n=72 510 n=22 284
No. (%) % % %
Age, y
MeanSD 77.37.4 77.77.4 77.47.4 76.57.1*
66 to 75 51 010 (45.0) 42.6 44.3 49.3*
76 to 85 44 751 (39.5) 40.2 39.7 38.2
86+ 17 535 (15.5) 17.2 16.0 12.5
Women 61 555 (54.3) 55.1 53.7 55.7
Race/ethnicity
White 95 481 (84.3) 83.8 85.5 80.5*
Black 9700 (8.6) 9.0 7.7 10.9*
Hispanic 3413 (3.0) 3.2 2.6 4.0
Asian 2504 (2.2) 1.9 2.2 2.5
Other 2198 (1.9) 2.1 1.9 2.1
Dual eligibility† 28 462 (25.1) 23.6 24.9 27.1
Baseline CCI
MeanSD 2.52.3 2.82.4* 2.52.3 2.42.3
0 22 608 (20.0) 17.4 19.8 22.6
1 or 2 43 540 (38.4) 36.5 38.7 39.3
3 to 5 34 947 (30.8) 33.1 31.0 28.5
6 to 8 9868 (8.7) 10.4 8.6 7.6
≥9 2333 (2.1) 2.6 2.0 1.9
Baseline comorbidities
Prior AMI‡ 5228 (4.6) 5.4 4.6 4.0
Dementia/Alzheimer’s disease§ 11 574 (10.2) 12.1 9.9 9.7
Depression 17 464 (15.4) 17.3 15.0 15.3
CABG 1136 (1.0) 1.1 1.0 1.0
PTCA/stent 7441 (6.6) 7.2 6.6 5.8
IHD 68 689 (60.6) 64.1 61.4 55.4*
Rhabdomyolysis/myopathy 7553 (6.7) 7.6 6.3 7.0
Index admission
CABG 6988 (6.2) 5.3 6.0 7.6
PTCA/stent 41 596 (36.7) 30.3* 36.4 43.1*
Cardiac catheterization 64 954 (57.3) 51.4* 56.8 63.9*
Cardiac dysrhythmias 35 365 (31.2) 31.7 31.6 29.4
Acute renal failure 17 876 (15.8) 17.7 15.5 14.9
Length of stay, d
MeanSD 5.35.0 5.75.8 5.24.8 5.34.9
1 to 3 49 896 (44.0) 40.6 44.7 44.9
4 to 6 35 187 (31.1) 31.6 31.1 30.4
Continued
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and 12-month post-discharge periods. Given the conditional
nature of the outcome (eg, a patient with PDC <40% before
their AMI could have “no change” in adherence or an
“increase” but would not be able to “decrease”), (10) a single
sensitivity analysis on the 3-level outcome using PROC
NLMIXED in SAS defined the likelihood function as conditional
on the pre-AMI adherence category. Finally, (11) a linear
regression model was developed for the continuous adher-
ence change outcome (post-AMI PDC minus pre-AMI PDC).
All analyses were conducted with SAS 9.4 (SAS Institute
Inc).
Results
A total of 113 296 prevalent statin users met our study
eligibility criteria. The distributions of sociodemographic and
clinical characteristics stratified by statin adherence change
categories are displayed in Table 1. Most patients were aged
66 to 85 years (84.5%), female (54.3%), and white (84.3%),
and 5228 (4.6%) had an AMI in the 12 months before their
index AMI. Overall 17 186 patients (15.2%) did not follow-up
with either a cardiologist or PCP within 30 days of hospital
discharge. See Tables S1 through S3 for a full list of the
distribution of population characteristics stratified by adher-
ence change, pre-AMI adherence, and post-AMI adherence.
Of the 756 059 prescription fills used to measure adher-
ence, 80.4% and 15.1% had a 30- and 90-day supply,
respectively. After index AMI hospitalization, 22 284 (19.7%)
patients had an increase in statin adherence, 18 502 (16.3%)
had a decrease, and 72 510 (64.0%) had no categorical
change in adherence (Figure 4). Patient characteristics asso-
ciated with different categories of adherence change are
presented in Table 1.
Model 1 Results: 3-Level Multinomial Regression
The associations of patient sociodemographic and clinical
characteristics with statin adherence change from the 3-level
multinomial logistic regression model (model 1) are presented
in Table 2. Compared with white patients, black patients were
more likely to have decreased adherence (model 1: OR, 1.21;
99% CI, 1.12–1.31) or increased adherence (OR, 1.14; 99% CI,
1.05–1.23) than to have no change in adherence. Hispanic
patients had similar patterns of adherence change compared
with white patients. Patients dually enrolled in both Medicare
and Medicaid were less likely to have decreased adherence
(OR, 0.80; 99% CI, 0.75–0.84) and more likely to have
increased adherence (OR, 1.18; 99% CI, 1.11–1.25) than to
have no change in adherence. Patients with greater chronic
disease burden (ie, higher CCI scores) were more likely to
have decreases in adherence and less likely to have increases
compared with no change in adherence. The association of
statin adherence change with patients receiving invasive
procedures during the index hospital, such as CABG or PTCA/
stent, had the inverse relationship; these patients were less
likely to have decreases in adherence and more likely to have
increases in adherence. Finally, as length of stay increased,
decreased statin adherence was typically more likely.
The association of follow-up with clinicians and the 3-level
adherence change outcome can be seen in Figure 5. Patients
who followed up with only a PCP compared with no follow-up
Table 1. Continued
Patient Characteristics
Total
Adherence Change
Decrease No Change Increase
N=113 296 n=18 502 n=72 510 n=22 284
No. (%) % % %
7 to 11 19 525 (17.2) 18.9 17.0 16.7
12+ 8688 (7.7) 8.8 7.3 8.1
30-d follow-up
None 17 186 (15.2) 15.8 15.1 14.9
PCP onlyk 33 332 (29.4) 31.0 29.4 28.0
Cardiologist only 20 292 (17.9) 16.2 18.1 18.8
Both 42 486 (37.5) 37.0 37.4 38.3
See Table S1 for a full list of patient characteristics. AMI indicates acute myocardial infarction; CABG, coronary artery bypass surgery; IHD, ischemic heart disease; PCP, primary care
provider; PTCA, percutaneous transluminal coronary angioplasty; SD, standard deviation.
*Absolute standardized difference ≥0.10 with no change in statin adherence as the reference group.
†Enrolled in Medicare and Medicaid.
‡Charlson Comorbidity Index (CCI) definition.
§Medicare Chronic Condition Data Warehouse definition.
kPrimary care physician, physician assistant, or nurse practitioner.
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within 30 days after the index discharge date had an 8%
increase in the likelihood of an increase in adherence (OR,
1.08; 99% CI, 1.00–1.16) compared with no change in
adherence. Follow-up with a cardiologist (OR, 1.15; 99% CI,
1.05–1.25) or both types of providers (OR, 1.21; 99% CI,
1.12–1.30) had a stronger association with an increase in
adherence. The association of clinician follow-up with a
decrease in adherence was not significant except for patients
who followed up with a cardiologist; these patients were less
likely to have a decrease in adherence than no change in
adherence (OR, 0.91; 99% CI, 0.84–0.98) compared with
patients with no follow-up. See Table S4 for the full list of
results for model 1.
Model 2 Results: 5-Level Multinomial Regression
Results using the 5-level adherence change outcome were
consistent with results using the 3-level outcome but provided
additional insight into patient characteristics that were
associated with a major increase or a major decrease in
statin adherence. Results from the 5-level multinomial logistic
regression model (model 2) are presented in Table 3. Patients
enrolled in both Medicare and Medicaid were 13% more likely
to have a moderate increase in adherence (model 2: OR, 1.13;
99% CI, 1.06–1.20) and, to a greater extent, they were 46%
more likely to have a major increase in adherence (OR, 1.46;
99% CI, 1.31–1.63). Patients who had an invasive procedure
such as CABG during their index hospital admission were 37%
less likely to have a major decrease (model 2: OR, 0.73; 99%
CI, 0.59–0.89) and 25% less likely to have a moderate
decrease in adherence (OR, 0.80; 99% CI, 0.71–0.91); they
were also 28% more likely to have a moderate increase (OR,
1.28; 99% CI, 1.15–1.43) and 77% more likely to have a major
increase in statin adherence (OR, 1.77; 99% CI, 1.46–2.14).
Patients with a PTCA/stent procedure during index hospital-
ization had similar patterns of adherence change.
Figure 6 shows that follow-up with a PCP within 30 days
after index hospital discharge trended towards an association
with a moderate increase in adherence (OR, 1.07; 99% CI,
0.99–1.15) and a major increase in adherence (OR, 1.10; 99%
CI, 0.96–1.27). Seeing a cardiologist was associated with a
13% increase in the likelihood of a moderate increase in
adherence (OR, 1.13; 99% CI, 1.03–1.23) and a 27% increase
in the likelihood of a major increase in adherence (OR, 1.27;
99% CI, 1.09–1.48). Follow-up with both a cardiologist and a
PCP (OR, 1.16; 99% CI, 1.08–1.26) was associated with a
moderate adherence increase compared with no follow-up;
follow-up with both of these providers also had a greater
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Figure 4. Distribution of post-AMI adherence stratified by pre-AMI adherence. AMI indicates acute
myocardial infarction; PDC, proportion of days covered.
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impact on the odds of a major increase in adherence (OR,
1.48; 99% CI, 1.29–1.69). See Table S5 for the full list of
results for model 2.
Sensitivity Analyses
Our sensitivity analyses found mostly similar and consistent
results that did not change the interpretation of our findings
from model 1 (Tables S6 through S10). When patient eligibility
was restricted to those who survived at least 6 months post-
hospital discharge, a CCI score of 9+ compared with 0 was no
longer statistically associated with increased adherence
(Table S7 in the “post-AMI 6-month survival” model; OR,
0.82 [99% CI, 0.65–1.04]). The sensitivity analysis with
adherence measured over 12 months in the pre- and post-
AMI periods showed similar and consistent results, although
fewer patients had increased and more patients had
decreased statin adherence (Figure S1). When investigating
1-year adherence changes, black patients were still likely to
have reduced adherence (Table S8; OR, 1.17; 99% CI, 1.09–
1.26) but were no longer as likely to have increased
adherence (OR, 1.05; 99% CI, 0.96–1.15). In the sensitivity
analysis using a likelihood function conditional on pre-AMI
adherence, black patients (OR, 0.94; 99% CI, 0.86–1.02) and
Hispanic patients (OR, 1.09; 99% CI, 0.94–1.25) were no
longer more likely than white patients to have increased
adherence (Table S9).
Discussion
In a cohort of 113 296 Medicare beneficiaries who were
prevalent statin users before their index AMI hospitalization,
64% had no change in adherence, 20% had increased
Table 2. Association Between Patient Characteristics and
3-Level Statin Adherence Change After an AMI
Patient Characteristics
Model 1: 3-Level Adherence Change*
Odds Ratio (99% CI)
(“No Change” as Reference)
Decrease Increase
Age, y
66 to 75 1. 1.
76 to 85 0.99 (0.94–1.04) 0.97 (0.92–1.02)
86+ 0.99 (0.92–1.06) 0.88 (0.81–0.95)
Women 1.03 (0.98–1.08) 1.06 (1.01–1.12)
Race/ethnicity
White 1. 1.
Black 1.21 (1.12–1.31) 1.14 (1.05–1.23)
Hispanic 1.30 (1.15–1.48) 1.29 (1.13–1.48)
Asian 0.97 (0.83–1.14) 1.16 (0.99–1.36)
Other 1.22 (1.05–1.42) 1.15 (0.97–1.36)
Dual eligibility† 0.80 (0.75–0.84) 1.18 (1.11–1.25)
Adjusted baseline CCI‡
0 1. 1.
1 or 2 1.03 (0.97–1.10) 0.88 (0.83–0.94)
3 to 5 1.08 (1.01–1.15) 0.84 (0.79–0.91)
6 to 8 1.14 (1.04–1.26) 0.81 (0.73–0.91)
9 or more 1.39 (1.19–1.62) 0.77 (0.64–0.93)
Baseline comorbidities
Prior AMI§ 1.04 (0.94–1.15) 0.92 (0.81–1.04)
Dementia/Alzheimer’s
diseasek
1.13 (1.06–1.21) 1.05 (0.97–1.14)
Depression 1.11 (1.05–1.18) 1.02 (0.95–1.09)
CABG 1.13 (0.92–1.39) 1.28 (1.01–1.62)
PTCA/stent 1.12 (1.02–1.23) 0.85 (0.76–0.95)
Ischemic heart
disease
1.09 (1.04–1.15) 0.84 (0.79–0.89)
Rhabdomyolysis/
myopathy
1.15 (1.05–1.24) 1.01 (0.92–1.11)
Index admission
CABG 0.78 (0.71–0.87) 1.34 (1.21–1.49)
PTCA/stent 0.82 (0.78–0.87) 1.25 (1.17–1.32)
Cardiac
catheterization
1.03 (0.95–1.12) 1.09 (1.00–1.19)
Cardiac
dysrhythmias
1.00 (0.95–1.05) 0.93 (0.88–0.98)
Acute renal failure 1.05 (0.99–1.12) 1.00 (0.93–1.07)
Length of stay, d
1 to 3 1. 1.
4 to 6 1.05 (1.00–1.11) 1.00 (0.94–1.06)
Continued
Table 2. Continued
Patient Characteristics
Model 1: 3-Level Adherence Change*
Odds Ratio (99% CI)
(“No Change” as Reference)
Decrease Increase
7 to 11 1.14 (1.07–1.22) 1.02 (0.95–1.10)
12+ 1.27 (1.16–1.39) 1.08 (0.97–1.20)
Models were adjusted for all variables in the table as well as pre–acute myocardial
infarction (AMI) adherence, area-level household income, other baseline conditions,
concurrent use of other AMI secondary prevention medications, other events during the
index hospitalization, and 30-day follow-up care with a provider. See Table S4 for the full
list of results for model 1. CABG indicates coronary artery bypass surgery; CI, confidence
interval; IHD, ischemic heart disease; OR, odds ratio; PDC, proportion of days covered;
PTCA, percutaneous transluminal coronary angioplasty.
*Three-level multinomial logistic regression comparing decrease in adherence to no
change and comparing increase in adherence to no change.
†Enrolled in Medicare and Medicaid.
‡Charlson Comorbidity Index (CCI) score does not include counts for AMI and dementia.
§CCI definition.
kMedicare Chronic Condition Data Warehouse definition.
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adherence, and 16% had decreased adherence after hospital-
ization. Interestingly, both black and Hispanic patients
responded more sensitively to an AMI hospitalization com-
pared with white patients, with adherence changes likely in
both directions. Patients who had a greater burden of chronic
comorbidities were more likely to have decreased adherence
and less likely to have increased adherence. On the other
hand, patients who required invasive interventions during the
index hospitalization were more likely to have increases in
adherence after discharge. Notably, patients who followed up
with a PCP were only mildly more likely to have increased
adherence, but patients who saw a cardiologist or both a
cardiologist and a PCP appeared to have markedly greater
odds of having increased statin adherence.
Change in adherence to statins after an AMI has been
reported in a few prior studies.8–11 In a study that used a 5%
random sample of Medicare patients, Kronish et al8 found
that 33% of patients with pre-AMI PDC ≥80% became
nonadherent after an AMI, while 38% of patients with PDC
<80% became adherent after AMI. They also found that
patients with a greater baseline comorbidity burden were less
likely to change from nonadherent to adherent and were more
likely to change from adherent to nonadherent after an AMI.
Another study with 855 patients with type 2 diabetes mellitus
found that 26% of patients became more adherent and 20% of
patients became less adherent after incident cardiovascular
events.11 However, we found strong relationships with
adherence change after AMI associated with race/ethnicity
and CABG during hospitalization that were not found in these
earlier studies. Our larger sample size––based on a 100%
sample of Medicare fee-for-service beneficiaries––also
allowed us to investigate more risk factors and categorize
race/ethnicity more granularly than white patients compared
with all other groups.
In this study, we found that patients dually enrolled in
Medicare and Medicaid were less likely to have decreased
adherence and more likely to have a moderate or major
increase in statin adherence. Prior research also supports the
finding that lower out-of-pocket costs are associated with
better adherence to preventive medications after an AMI.23,24
Therefore, patients with Medicare who are eligible but not
enrolled in Medicaid or the low-income subsidy program may
benefit if providers and their clinical support staff inform
patients about these programs.
Similar to previous findings,8 patients with greater comor-
bidity burden at baseline were more likely to have decreased
adherence and less likely to have increased adherence after
AMI hospital discharge. It is also possible that clinicians
stopped preventative medications in patients with a short life
expectancy. When analyses were restricted to patients who
survived 6 months after hospital discharge, the magnitude of
the association between CCI and decreased adherence was
slightly weaker; however, this finding did not significantly
impact our interpretation of the results. Clinicians should
continue to emphasize the importance of preventive medica-
tions in patients with depression, a history of ischemic heart
disease, or multiple comorbidities. Given that greater comor-
bidity burden is associated with decreased adherence,
Figure 5. Association between follow-up care within 30 days of index hospital discharge and 3-level
statin adherence change after an acute myocardial infarction (AMI). Models were adjusted for
sociodemographic characteristics, pre-AMI adherence, baseline conditions and Charlson Comorbidity
Index, concurrent use of other AMI secondary prevention medications, and events during the index
hospitalization. See Table S4 for a full list of these variables and estimates. The 3-level multinomial
logistic regression compared a decrease in adherence with no change and compared an increase in
adherence with no change. *Primary care physician, physician assistant, or nurse practitioner. CI
indicates confidence interval; PCP, primary care provider.
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Table 3. Association Between Patient Characteristics and 5-Level Statin Adherence Change After an AMI
Patient Characteristics
Model 2: 5-Level Adherence Change*
Odds Ratio (99% CI)
(“No Change” as Reference)
Major Decrease Moderate Decrease Moderate Increase Major Increase
Age, y
66 to 75 1. 1. 1. 1.
76 to 85 0.95 (0.87–1.05) 1.00 (0.95–1.06) 0.96 (0.91–1.02) 1.01 (0.92–1.11)
86+ 0.99 (0.88–1.12) 0.98 (0.91–1.06) 0.86 (0.79–0.93) 0.94 (0.81–1.08)
Women 1.06 (0.97–1.15) 1.02 (0.97–1.07) 1.07 (1.01–1.12) 1.04 (0.95–1.14)
Race/ethnicity
White 1. 1. 1. 1.
Black 1.25 (1.07–1.45) 1.21 (1.11–1.32) 1.15 (1.06–1.25) 1.16 (1.01–1.34)
Hispanic 1.29 (1.00–1.64) 1.32 (1.15–1.52) 1.32 (1.15–1.51) 1.25 (1.00–1.58)
Asian 0.87 (0.64–1.19) 1.01 (0.84–1.20) 1.18 (1.00–1.39) 1.09 (0.82–1.47)
Other 1.19 (0.88–1.59) 1.24 (1.04–1.46) 1.14 (0.96–1.36) 1.27 (0.94–1.71)
Dual eligibility† 0.81 (0.73–0.90) 0.79 (0.74–0.84) 1.13 (1.06–1.20) 1.46 (1.31–1.63)
Adjusted baseline CCI‡
0 1. 1. 1. 1.
1 or 2 1.01 (0.90–1.14) 1.04 (0.97–1.11) 0.89 (0.83–0.95) 0.82 (0.73–0.92)
3 to 5 1.07 (0.94–1.22) 1.08 (1.00–1.17) 0.87 (0.81–0.94) 0.69 (0.61–0.79)
6 to 8 1.15 (0.96–1.37) 1.14 (1.02–1.27) 0.82 (0.73–0.92) 0.74 (0.61–0.91)
9 or more 1.37 (1.02–1.83) 1.40 (1.18–1.66) 0.81 (0.66–0.99) 0.58 (0.41–0.83)
Baseline comorbidities
Prior AMI§ 1.14 (0.95–1.38) 1.01 (0.90–1.13) 0.92 (0.81–1.05) 0.90 (0.72–1.14)
Dementia/Alzheimer’s diseasek 1.30 (1.15–1.47) 1.08 (1.00–1.17) 1.06 (0.97–1.15) 0.97 (0.83–1.14)
Depression 1.14 (1.02–1.28) 1.10 (1.03–1.18) 1.01 (0.94–1.09) 1.03 (0.91–1.16)
CABG 1.24 (0.84–1.83) 1.10 (0.87–1.38) 1.26 (0.99–1.61) 1.35 (0.85–2.17)
PTCA/stent 1.21 (1.02–1.45) 1.09 (0.99–1.21) 0.86 (0.77–0.96) 0.79 (0.64–0.97)
Ischemic heart disease 1.07 (0.97–1.18) 1.10 (1.04–1.17) 0.89 (0.84–0.94) 0.61 (0.56–0.68)
Rhabdomyolysis/myopathy 1.15 (0.98–1.35) 1.15 (1.04–1.26) 1.03 (0.94–1.14) 0.91 (0.77–1.08)
Index admission
CABG 0.73 (0.59–0.89) 0.80 (0.71–0.91) 1.28 (1.15–1.43) 1.77 (1.46–2.14)
PTCA/stent 0.80 (0.72–0.89) 0.83 (0.78–0.88) 1.19 (1.12–1.27) 1.60 (1.43–1.78)
Cardiac catheterization 0.99 (0.84–1.17) 1.04 (0.95–1.15) 1.07 (0.97–1.17) 1.20 (1.02–1.41)
Cardiac dysrhythmias 1.01 (0.92–1.10) 0.99 (0.94–1.05) 0.93 (0.88–0.98) 0.90 (0.82–0.99)
Acute renal failure 1.05 (0.94–1.17) 1.05 (0.98–1.13) 1.00 (0.93–1.07) 0.99 (0.87–1.13)
Length of stay, d
1 to 3 1. 1. 1. 1.
4 to 6 1.11 (1.01–1.23) 1.04 (0.98–1.10) 0.99 (0.93–1.05) 1.04 (0.94–1.16)
7 to 11 1.36 (1.21–1.53) 1.08 (1.01–1.17) 1.00 (0.93–1.08) 1.10 (0.96–1.25)
12+ 1.67 (1.42–1.96) 1.16 (1.05–1.28) 1.07 (0.96–1.19) 1.11 (0.91–1.34)
Models were adjusted for all variables in table as well as pre–acute myocardial infarction (AMI) adherence, area-level household income, other baseline conditions, concurrent use of other
AMI secondary prevention medications, other events during the index hospitalization, and 30-day follow-up care with a provider. See Table S5 for the full list of results for model 2. CABG,
coronary artery bypass surgery; CI, confidence interval; IHD, ischemic heart disease; OR, odds ratio; PDC, proportion of days covered; PTCA, percutaneous transluminal coronary
angioplasty.
*Five-level multinomial logistic regression model comparing all four outcomes in the table with the reference group of no change in adherence.
†Enrolled in Medicare and Medicaid.
‡Charlson Comorbidity Index (CCI) score does not include counts for AMI and dementia.
§CCI definition.
kMedicare Chronic Condition Data Warehouse definition.
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coordinated care with outpatient clinicians to manage these
other conditions has the potential to improve adherence to
preventive medications after an AMI, in addition to improving
patient health directly associated with these other conditions.
Further research is needed to completely understand the
association between comorbidity burden and statin adher-
ence change after an AMI.
Patients who required invasive procedures such as a CABG
or PTCA/stent during their hospitalization were more likely to
have increased adherence after an AMI. The finding that these
more severe hospitalizations may have acted as a “wake-up
call” to patients about the need for statin adherence also
aligns with the Sentinel Event Effect.25,26 Studies have shown
that perceived necessity for statins is associated with better
adherence27 and that illness severity, such as the need for
stents or CABG, is predictive of positive behavior change after
a cardiac event.28 While clinical severity often influences
which patients receive the most attention, our results suggest
that patients with “minor” AMIs may benefit as much if not
more from counseling if providers can utilize this event as a
teachable moment.
Our study also showed that complex patterns of statin
adherence change after an AMI were associated with race and
ethnicity. These complex patterns may suggest heterogeneity
in statin adherence change within these subgroups. Black and
Hispanic patients were more likely to have adherence
changes in both directions compared with white patients.
The associations between race/ethnicity and interactions
with the healthcare system are multifaceted, with biology,
culture, perceived racism, social support, socioeconomic
status, and structural racism among other factors playing a
role.29,30 Future hypothesis-driven studies are warranted to
further understand the complex associations of statin adher-
ence change within and between these race/ethnicity groups.
Figure 6. Association between follow-up care within 30 days of index hospital discharge and 5-level
statin adherence change after an acute myocardial infarction (AMI). Models were adjusted for
sociodemographic characteristics, pre-AMI adherence, baseline conditions and Charlson Comorbidity
Index, concurrent use of other AMI secondary prevention medications, and events during the index
hospitalization. See Table S5 for a full list of these variables and estimates. The 5-level multinomial
logistic regression model compared all four adherence change outcomes with the reference group of no
change in adherence. *Primary care physician, physician assistant, or nurse practitioner. CI indicates
confidence interval; PCP, primary care provider.
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Finally, an important finding from our study was that
follow-up with a clinician within 30 days of hospital discharge
was associated with increased adherence. Follow-up with a
clinician may not be a direct predictor of increased statin
adherence (ie, the same patients who decided to adhere to
their statins also decided it was important to follow up with a
clinician); however, current literature does support the view
that early follow-up with providers after a hospitalization as an
intervention can improve medication adherence20,31,32 and
clinical outcomes.33–35 In addition, we found that a cardiol-
ogist visit compared with no follow-up care was associated
with a major increase in adherence (pre-AMI PDC <40% to
post-AMI PDC ≥80%), while this association was not signif-
icant among patients who followed up with a PCP only. This
finding is intriguing, but more research is needed to verify and
fully understand these results. More importantly, however,
follow-up care had an even stronger association with
increased statin adherence among patients who followed up
with both a cardiologist and a PCP. This supports the
importance of collaborative team care and continuity of care
after hospital discharge.36,37 While our results may suggest
post-AMI follow-up that includes a cardiologist is the preferred
intervention, it is unrealistic that all patients who have an AMI
will be able to see a cardiologist. Previous research found that
a post-AMI intervention including pharmacist collaborative
care with primary care physicians and/or cardiologists
resulted in improved 1-year adherence for most secondary
prevention medications.38 If future research supports the
finding that increases in adherence are suboptimal among
patients who follow-up with a PCP only, then pharmacist
involvement in collaborative care transitions to synergistically
optimize medication utilization could be a potential interven-
tion worth considering, especially for patients not able to
follow-up with a cardiologist.
Study Limitations
This study has several limitations. Because administrative
claims are used for billing purposes and not designed for
research, there is the possibility of variable misclassification.
Some predictive factors (eg, smoking status) were not
available in the data. These may be important variables for
clinicians to consider and may also confound relationships
between other predictive factors and statin adherence
change. We followed existing standards using secondary
claims data for health services research to mitigate these
limitations. Second, several factors can result in measure-
ment error when administrative claims data are used to
measure adherence. Prescription fill data may overestimate
adherence as there is no information on whether patients
used the medication, and our data did not have information
available on the type of pharmacy (ie, physical versus mail-
order pharmacies) or whether automatic refill programs were
used; however, prescription fill records have been shown to
have good validity and correlation with other adherence mea-
sures––self-report, pill counts, and electronic devices39–41––
as well as clinical outcomes.3 It is also possible that
adherence was underestimated if prescriptions were paid
for outside of the Medicare Part D plan. However, research
has shown that this does not often happen for Medicare
beneficiaries, and even when it does, these claims are often
adjudicated into Part D records.42–44 Medicare patients are
also less likely to use medication samples than those in the
privately insured population.45 Third, we did not have a control
group in this study, but previous research using two control
groups––patients without a hospitalization and patients
hospitalized for pneumonia––found that AMI hospitalizations
were associated with changes in statin adherence.8
Study Strengths
This study possesses several strengths. It is the first to
employ a nationally representative sample of all Medicare fee-
for-service beneficiaries who had an AMI in the period 2008–
2010, enabling us to investigate more risk factors with
improved generalizability. We also investigated the impact of
post-AMI follow-up with a clinician, which was noted as an
important factor in previous research on this topic.8 Further,
our several definitions of adherence change allowed assess-
ment of varying magnitudes of adherence change and the
inclusion of all study patients in a single statistical model.
Conclusions
An AMI hospitalization may lead to changes in statin
adherence among patients already taking these medications.
The direction of statin adherence change after an AMI varied
by patient sociodemographic and clinical characteristics.
Improved adherence was also associated with post-discharge
follow-up care, particularly among patients who saw a
cardiologist or both a PCP and a cardiologist. Innovative
strategies that address these complex changes in medication
adherence after an AMI and emphasize continuity of care are
needed to improve post-AMI secondary prevention.
Sources of Funding
This study is supported in part by the National Institutes of
Health’s National Institute on Aging grant 1R01AG046267-
01A1 (principal investigator: Fang) and 1R21AG043668-01A1
(principal investigator: Fang). The findings and conclusions in
this article are those of the authors, who are responsible for
its contents, and do not necessarily represent the views of the
DOI: 10.1161/JAHA.117.007106 Journal of the American Heart Association 13
Changes in Statin Adherence After Acute Myocardial Infarction Hickson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
funding agency. Dr Hickson received support from the
American Foundation for Pharmaceutical Education as the
2015 Phi Lambda Sigma First Year Graduate School Fellow.
Disclosures
Hickson, Annis, Killeya-Jones, and Fang have no conflicts of
interests to report. Robinson worked on grants from Amarin,
Amgen, Astra-Zeneca, Eli Lilly, Esai, GlaxoSmithKline, Merck,
Pfizer, Regeneron/Sanofi, and Takeda. Robinson was a
consultant for Amgen, Pfizer, and Regeneron/Sanofi (signif-
icant), and Akcea/Ionis, Eli Lilly, Esperion, and Merck
(modest). Korhonen worked on grants from the Social
Insurance Institution of Finland. Cole is a paid (part-time)
employee of IBM Watson Health (significant).
References
1. Choudhry NK, Glynn RJ, Avorn J, Lee JL, Brennan TA, Reisman L, Toscano M,
Levin R, Matlin OS, Antman EM, Shrank WH. Untangling the relationship
between medication adherence and post-myocardial infarction outcomes:
medication adherence and clinical outcomes. Am Heart J. 2014;167:51–58.e5.
2. Kuepper-Nybelen J, Hellmich M, Abbas S, Ihle P, Griebenow R, Schubert I.
Association of long-term adherence to evidence-based combination drug
therapy after acute myocardial infarction with all-cause mortality. A prospective
cohort study based on claims data. Eur J Clin Pharmacol. 2012;68:1451–1460.
3. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to
evidence-based pharmacotherapy and long-term mortality after acute myocar-
dial infarction. JAMA. 2007;297:177–186.
4. Zhang Y, Kaplan CM, Baik SH, Chang CC, Lave JR. Medication adherence and
readmission after myocardial infarction in the Medicare population. Am J
Manag Care. 2014;20:e498–e505.
5. Schnipper JL, Kirwin JL, Cotugno MC, Wahlstrom SA, Brown BA, Tarvin E,
Kachalia A, Horng M, Roy CL, McKean SC, Bates DW. Role of pharmacist
counseling in preventing adverse drug events after hospitalization. Arch Intern
Med. 2006;166:565–571.
6. Garcia-Caballos M, Ramos-Diaz F, Jimenez-Moleon JJ, Bueno-Cavanillas A.
Drug-related problems in older people after hospital discharge and interven-
tions to reduce them. Age Ageing. 2010;39:430–438.
7. Kripalani S, Henderson LE, Jacobson TA, Vaccarino V. Medication use among
inner-city patients after hospital discharge: patient-reported barriers and
solutions. Mayo Clin Proc. 2008;83:529–535.
8. Kronish IM, Ross JS, Zhao H, Muntner P. The impact of hospitalization for acute
myocardial infarction on adherence to statins among older adults. Circ
Cardiovasc Qual Outcomes. 2016;9:364–371.
9. Beloin-Jubinville B, Joly-Mischlich T, Rouleau ED, Noiseux P, Blais L, Forget A,
Beauchesne MF. Does hospitalization influence patients’ medication adher-
ence and community pharmacists’ interventions? Ann Pharmacother.
2013;47:1143–1152.
10. Cohen MJ, Shaykevich S, Cawthon C, Kripalani S, Paasche-Orlow MK,
Schnipper JL. Predictors of medication adherence postdischarge: the impact
of patient age, insurance status, and prior adherence. J Hosp Med.
2012;7:470–475.
11. de Vries FM, Denig P, Vegter S, Bos HJ, Postma MJ, Hak E. Does a
cardiovascular event change adherence to statin treatment in patients with
type 2 diabetes? A matched cohort design. Curr Med Res Opin. 2015;31:595–
602.
12. Choma NN, Griffin MR, Huang RL, Mitchel EF Jr, Kaltenbach LA, Gideon P,
Stratton SM, Roumie CL. An algorithm to identify incident myocardial
infarction using Medicaid data. Pharmacoepidemiol Drug Saf. 2009;18:1064–
1071.
13. Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH.
Accuracy of Medicare claims-based diagnosis of acute myocardial infarction:
estimating positive predictive value on the basis of review of hospital records.
Am Heart J. 2004;148:99–104.
14. Buccaneer, Computer Systems and Services, Inc. Chronic condition data
warehouse user manual. 2009;1.5.
15. Romano PS, Roos LL, Jollis JG. Adapting a clinical comorbidity index for use
with ICD-9-CM administrative data: differing perspectives. J Clin Epidemiol.
1993;46:1075–1079; discussion 1081-90.
16. Andrade SE, Graham DJ, Staffa JA, Schech SD, Shatin D, La Grenade L,
Goodman MJ, Platt R, Gurwitz JH, Chan KA. Health plan administrative
databases can efficiently identify serious myopathy and rhabdomyolysis. J Clin
Epidemiol. 2005;58:171–174.
17. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman
JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL,
Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ,
Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK. ACC/AHA
guidelines for the management of patients with ST-elevation myocardial
infarction: a report of the American College of Cardiology/American Heart
Association Task Force on Practice Guidelines (Committee to Revise the 1999
Guidelines for the Management of Patients with Acute Myocardial Infarction).
Circulation. 2004;110:e82–e292.
18. Yang D, Dalton JE. A unified approach to measuring the effect size between
two groups using SAS. SAS Institute Inc. 2012. Proceedings of the SAS
Global Forum 2012 Conference. Statistics and Data Analysis, Paper 335–2012.
Cary, NC: SAS Institute Inc. http://support.sas.com/resources/papers/
proceedings12/335-2012.pdf. Accessed June 21, 2016.
19. Normand ST, Landrum MB, Guadagnoli E, Ayanian JZ, Ryan TJ, Cleary PD,
McNeil BJ. Validating recommendations for coronary angiography following
acute myocardial infarction in the elderly: a matched analysis using propensity
scores. J Clin Epidemiol. 2001;54:387–398.
20. Faridi KF, Peterson ED, McCoy LA, Thomas L, Enriquez J, Wang TY. Timing of
first postdischarge follow-up and medication adherence after acute myocardial
infarction. JAMA Cardiol. 2016;1:147–155.
21. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH,
Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS,
Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM,
LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B,
Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM,
Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA
guideline on the treatment of blood cholesterol to reduce atherosclerotic
cardiovascular risk in adults: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines. Circulation.
2014;129:S1–S45.
22. Scranton RE, Young M, Lawler E, Solomon D, Gagnon D, Gaziano JM. Statin use
and fracture risk: study of a US veterans population. Arch Intern Med.
2005;165:2007–2012.
23. Choudhry NK, Avorn J, Glynn RJ, Antman EM, Schneeweiss S, Toscano M,
Reisman L, Fernandes J, Spettell C, Lee JL, Levin R, Brennan T, Shrank WH. Full
coverage for preventive medications after myocardial infarction. N Engl J Med.
2011;365:2088–2097.
24. Stuart B, Davidoff A, Erten M, Gottlieb SS, Dai M, Shaffer T, Zuckerman IH,
Simoni-Wastila L, Bryant-Comstock L, Shenolikar R. How Medicare Part D
benefit phases affect adherence with evidence-based medications following
acute myocardial infarction. Health Serv Res. 2013;48:1960–1977.
25. Boudreaux ED, Bock B, O’Hea E. When an event sparks behavior change: an
introduction to the sentinel event method of dynamic model building and its
application to emergency medicine. Acad Emerg Med. 2012;19:329–335.
26. McBride CM, Emmons KM, Lipkus IM. Understanding the potential of
teachable moments: the case of smoking cessation. Health Educ Res.
2003;18:156–170.
27. Allen LaPointe NM, Ou FS, Calvert SB, Melloni C, Stafford JA, Harding T,
Peterson ED, Alexander KP. Association between patient beliefs and
medication adherence following hospitalization for acute coronary syndrome.
Am Heart J. 2011;161:855–863.
28. O’Hea E, Abar B, Bock B, Chapman G, Boudreaux ED. Understanding smoking
after acute illness: an application of the sentinel event method. Psychol Health.
2015;30:879–896.
29. Cuffee YL, Hargraves JL, Rosal M, Briesacher BA, Schoenthaler A, Person S,
Hullett S, Allison J. Reported racial discrimination, trust in physicians, and
medication adherence among inner-city African Americans with hypertension.
Am J Public Health. 2013;103:e55–e62.
30. Smedley BD, Stith AY, Nelson AR. Institute of Medicine, Committee on
Understanding and Eliminating Racial and Ethnic Disparities in Health Care.
Unequal treatment: confronting racial and ethnic disparities in health care.
2003.
31. Mathews R, Peterson ED, Honeycutt E, Chin CT, Effron MB, Zettler M, Fonarow
GC, Henry TD, Wang TY. Early medication nonadherence after acute
myocardial infarction: insights into actionable opportunities from the TReat-
ment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment
Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study.
Circ Cardiovasc Qual Outcomes. 2015;8:347–356.
DOI: 10.1161/JAHA.117.007106 Journal of the American Heart Association 14
Changes in Statin Adherence After Acute Myocardial Infarction Hickson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
32. Shah ND, Dunlay SM, Ting HH, Montori VM, Thomas RJ, Wagie AE, Roger VL.
Long-term medication adherence after myocardial infarction: experience of a
community. Am J Med. 2009;122:961.e7–e13.
33. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the
Medicare fee-for-service program. N Engl J Med. 2009;360:1418–1428.
34. Misky GJ, Wald HL, Coleman EA. Post-hospitalization transitions: examining
the effects of timing of primary care provider follow-up. J Hosp Med.
2010;5:392–397.
35. Coleman EA, Parry C, Chalmers S, Min SJ. The care transitions intervention:
results of a randomized controlled trial. Arch Intern Med. 2006;166:1822–
1828.
36. Brookhart MA, Patrick AR, Schneeweiss S, Avorn J, Dormuth C, Shrank W, van
Wijk BL, Cadarette SM, Canning CF, Solomon DH. Physician follow-up and
provider continuity are associated with long-term medication adherence: a
study of the dynamics of statin use. Arch Intern Med. 2007;167:847–852.
37. Kripalani S, Jackson AT, Schnipper JL, Coleman EA. Promoting effective
transitions of care at hospital discharge: a review of key issues for hospitalists.
J Hosp Med. 2007;2:314–323.
38. Ho PM, Lambert-Kerzner A, Carey EP, Fahdi IE, Bryson CL, Melnyk SD,
Bosworth HB, Radcliff T, Davis R, Mun H, Weaver J, Barnett C, Baron A, Del
Giacco EJ. Multifaceted intervention to improve medication adherence and
secondary prevention measures after acute coronary syndrome hospital
discharge: a randomized clinical trial. JAMA Intern Med. 2014;174:
186–193.
39. Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods
to assess medication adherence and classify nonadherence. Ann Pharma-
cother. 2009;43:413–422.
40. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in
drug exposure assessment. J Clin Epidemiol. 1997;50:619–625.
41. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy
records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105–
116.
42. Stuart B, Loh FE. Medicare Part D enrollees’ use of out-of-plan discounted
generic drugs. J Am Geriatr Soc. 2012;60:387–388.
43. Roberto PN, Stuart B. Out-of-plan medication in Medicare Part D. Am J Manag
Care. 2014;20:743–748.
44. Zhou L, Stearns SC, Thudium EM, Alburikan KA, Rodgers JE. Assessing
Medicare Part D claim completeness using medication self-reports: the role of
veteran status and Generic Drug Discount Programs. Med Care. 2015;53:463–
470.
45. Brown JD, Doshi PA, Talbert JC. Utilization of free medication samples in the
United States in a nationally representative sample: 2009–2013. Res Social
Adm Pharm. 2016;13:193–200.
DOI: 10.1161/JAHA.117.007106 Journal of the American Heart Association 15
Changes in Statin Adherence After Acute Myocardial Infarction Hickson et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
  
 
 
 
Supplemental Material  
Table S1. Patient characteristics stratified by change in statin adherence after AMI. 
   Adherence Change 
 Total Decrease No Change Increase 
 N=113,296 N=18,502 N=72,510 N=22,284 
Patient Characteristics N (%) % [ASD] % [ASD] % [ASD] 
Age     
   Mean ± SD 77.3 ± 7.4 77.7 ± 7.4 [4.5] 77.4 ± 7.4 [Ref] 76.5 ± 7.1 [11.9] 
   66-75 51,010 (45.0) 42.6 [3.4] 44.3 [Ref] 49.3 [10.0] 
   76-85 44,751 (39.5) 40.2 [0.9] 39.7 [Ref] 38.2 [3.1] 
   86+ 17,535 (15.5) 17.2 [3.3] 16.0 [Ref] 12.5 [9.9] 
Female 61,555 (54.3) 55.1 [2.7] 53.7 [Ref] 55.7 [3.9] 
Race/ethnicity     
   White 95,481 (84.3) 83.8 [4.7] 85.5 [Ref] 80.5 [13.5] 
   Black 9,700 (8.6) 9.0 [4.5] 7.7 [Ref] 10.9 [10.9] 
   Hispanic 3,413 (3.0) 3.2 [3.2] 2.6 [Ref] 4.0 [7.8] 
   Asian 2,504 (2.2) 1.9 [2.2] 2.2 [Ref] 2.5 [1.6] 
   Other 2,198 (1.9) 2.1 [1.7] 1.9 [Ref] 2.1 [1.8] 
Dual eligibility* 28,462 (25.1) 23.6 [3.0] 24.9 [Ref] 27.1 [5.1] 
Household income†     
   ≤$30,000 53,388 (47.1) 47.7 [2.2] 46.6 [Ref] 48.5 [3.8] 
   $30,001-60,000 46,749 (41.3) 40.8 [1.8] 41.7 [Ref] 40.1 [3.3] 
   $60,001-100,000 10,579 (9.3) 9.2 [0.7] 9.4 [Ref] 9.2 [0.5] 
   $100,001-150,000 1,963 (1.7) 1.8 [0.4] 1.7 [Ref] 1.6 [0.9] 
   >$150,000 617 (0.5) 0.5 [1.4] 0.6 [Ref] 0.5 [0.3] 
CCI comorbidities     
   AMI 5,228 (4.6) 5.4 [3.5] 4.6 [Ref] 4.0 [3.0] 
   Cancer 13,792 (12.2) 13.3 [3.5] 12.1 [Ref] 11.4 [2.2] 
   CeVD 20,900 (18.4) 20.1 [4.6] 18.3 [Ref] 17.6 [1.9] 
   CHF 34,328 (30.3) 34.4 [8.4] 30.5 [Ref] 26.3 [9.4] 
   COPD 31,448 (27.8) 29.8 [5.0] 27.6 [Ref] 26.7 [2.0] 
   Dementia 3,303 (2.9) 3.6 [4.7] 2.8 [Ref] 2.8 [0.2] 
   Diabetes 54,209 (47.8) 49.4 [2.8] 48.0 [Ref] 46.2 [3.5] 
   Liver disease 2,157 (1.9) 2.3 [3.6] 1.8 [Ref] 1.9 [1.0] 
   Metastatic cancer 1,702 (1.5) 2.0 [4.8] 1.4 [Ref] 1.4 [0.1] 
   Para-/hemiplagia 1,236 (1.1) 1.3 [2.0] 1.0 [Ref] 1.1 [0.9] 
   Peptic ulcer disease 1,994 (1.8) 2.0 [2.4] 1.7 [Ref] 1.9 [2.0] 
   PVD 26,580 (2.3) 25.6 [4.8] 23.5 [Ref] 21.6 [4.4] 
   Renal disease 21,592 (19.1) 21.2 [5.3] 19.1 [Ref] 17.1 [5.4] 
   Rheumatic disease 4,204 (3.7) 4.0 [2.0] 3.6 [Ref] 3.7 [0.2] 
     
     
   Adherence Change 
 Total Decrease No Change Increase 
 N=113,296 N=18,502 N=72,510 N=22,284 
Patient Characteristics N (%) % [ASD] % [ASD] % [ASD] 
CCI     
   Mean ± SD 2.5 ± 2.3 2.8 ± 2.4 [11.1] 2.5 ± 2.3 [Ref] 2.4 ± 2.3 [7.1] 
   0 22,608 (20.0) 17.4 [6.2] 19.8 [Ref] 22.6 [7.0] 
   1-2 43,540 (38.4) 36.5 [4.5] 38.7 [Ref] 39.3 [1.3] 
   3-5 34,947 (30.8) 33.1 [4.4] 31.0 [Ref] 28.5 [5.5] 
   6-8 9,868 (8.7) 10.4 [6.2] 8.6 [Ref] 7.6 [3.5] 
   9 or more 2,333 (2.1) 2.6 [4.6] 2.0 [Ref] 1.9 [0.3] 
Other comorbidities     
   Dementia/Alz‡ 11,574 (10.2) 12.1 [7.0] 9.9 [Ref] 9.7 [0.7] 
   Depression 17,464 (15.4) 17.3 [6.2] 15.0 [Ref] 15.3 [0.8] 
   CABG 1,136 (1.0) 1.1 [1.4] 1.0 [Ref] 1.0 [0.1] 
   PTCA/stent 7,441 (6.6) 7.2 [2.4] 6.6 [Ref] 5.8 [3.5] 
   IHD 68,689 (60.6) 64.1 [5.6] 61.4 [Ref] 55.4 [12.1] 
   Unstable angina 6,112 (5.4) 6.0 [2.3] 5.5 [Ref] 4.6 [3.9] 
   Lipid abnormalities 101,285 (89.4) 89.7 [0.5] 89.6 [Ref] 88.6 [3.0] 
   Rhabdo/myopathy 7,553 (6.7) 7.6 [5.1] 6.3 [Ref] 7.0 [3.1] 
Pre-AMI medications     
   Beta-blocker 73,425 (64.8) 65.4 [2.0] 66.4 [Ref] 59.3 [14.8] 
   ACE inhibitor/ARB 75,501 (66.6) 67.0 [0.8] 67.4 [Ref] 64.0 [7.2] 
Index admission     
   Subend infarction 90,299 (79.7) 81.4 [2.8] 80.3 [Ref] 76.3 [9.8] 
   CABG 6,988 (6.2) 5.3 [2.9] 6.0 [Ref] 7.6 [6.5] 
   PTCA/stent 41,596 (36.7) 30.3 [12.9] 36.4 [Ref] 43.1 [13.7] 
   Platelet inhibitors 4,919 (4.3) 3.6 [4.1] 4.4 [Ref] 4.9 [2.8] 
   Cardiac cath 64,954 (57.3) 51.4 [10.8] 56.8 [Ref] 63.9 [14.5] 
   Angiocardiography 65,107 (57.5) 51.4 [11.7] 57.2 [Ref] 63.3 [12.4] 
   Cardiogenic shock 2,484 (2.2) 2.2 [0.8] 2.1 [Ref] 2.6 [3.5] 
   Dysrhythmias 35,365 (31.2) 31.7 [0.0] 31.6 [Ref] 29.4 [4.8] 
   Hypotension 5,679 (5.0) 5.1 [0.5] 5.0 [Ref] 5.1 [0.4] 
   Acute renal failure 17,876 (15.8) 17.7 [5.8] 15.5 [Ref] 14.9 [1.7] 
   Heart failure 45,681 (40.3) 43.3 [6.0] 40.4 [Ref] 37.7 [5.5] 
   Length of stay (days)     
      Mean ± SD 5.3 ± 5.0 5.7 ± 5.8 [9.3] 5.2 ± 4.8 [Ref] 5.3 ± 4.9 [1.7] 
      1-3 49,896 (44.0) 40.6 [8.1] 44.7 [Ref] 44.9 [0.4] 
      4-6 35,187 (31.1) 31.6 [1.1] 31.1 [Ref] 30.4 [1.6] 
      7-11 19,525 (17.2) 18.9 [5.1] 17.0 [Ref] 16.7 [0.7] 
      12+ 8,688 (7.7) 8.8 [5.8] 7.3 [Ref] 8.1 [3.0] 
   Adherence Change 
 Total Decrease No Change Increase 
 N=113,296 N=18,502 N=72,510 N=22,284 
Patient Characteristics N (%) % [ASD] % [ASD] % [ASD] 
   Intensive care     
      None 28,655 (25.3) 25.6 [0.6] 25.8 [Ref] 23.3 [5.8] 
      CCU only 26,295 (23.2) 22.3 [1.8] 23.1 [Ref] 24.4 [3.2] 
      ICU only 46,625 (41.2) 42.1 [2.2] 41.0 [Ref] 40.8 [0.4] 
      Both 11,721 (10.3) 10.0 [0.1] 10.1 [Ref] 11.4 [4.3] 
   Cardiologist consult 97,977 (86.5) 85.3 [3.1] 86.4 [Ref] 87.7 [3.8] 
30-day follow-up     
   None 17,186 (15.2) 15.8 [1.9] 15.1 [Ref] 14.9 [0.4] 
   PCP only§ 33,332 (29.4) 31.0 [3.5] 29.4 [Ref] 28.0 [3.2] 
   Cardiologist only 20,292 (17.9) 16.2 [5.1] 18.1 [Ref] 18.8 [1.9] 
   Both 42,486 (37.5) 37.0 [0.7] 37.4 [Ref] 38.3 [1.8] 
Simvastatin ADD 
changeǁ 
2.7 ± 34.3 -8.6 ± 36.4 [35.4] 3.5 ± 32.0 [Ref] 9.7 ± 37.0 [17.8] 
Pre-AMI statin#     
   Low intensity 12,216 (10.8) 10.4 [1.5] 10.9 [Ref] 10.8 [0.1] 
   Moderate intensity 76,914 (67.9) 67.5 [1.1] 68.0 [Ref] 67.9 [0.2] 
   High intensity 24,166 (21.3) 22.4 [2.4] 21.1 [Ref] 21.2 [0.3] 
Post-AMI statin#     
   Low intensity 9,442 (8.3) 9.4 [3.4] 8.4 [Ref] 7.2 [4.4] 
   Moderate intensity 72,897 (6.4) 65.7 [2.3] 64.6 [Ref] 62.5 [4.2] 
   High intensity 30,957 (27.3) 25.0 [4.7] 27.0 [Ref] 30.2 [7.1] 
Pre-AMI PDC     
   <40% 18,205 (16.1) 0.0 [49.7] 11.0 [Ref] 45.9 [83.8] 
   40-79.9% 24,373 (21.5) 26.1 [41.7] 10.3 [Ref] 54.1 [106.0] 
   ≥80% 70,718 (62.4) 73.9 [11.1] 78.7 [Ref] 0.0 [271.5] 
Post-AMI PDC     
   <40% 17,104 (15.1) 49.3 [91.9] 11.0 [Ref] 0.0 [49.7] 
   40-79.9% 21,348 (18.8) 50.7 [97.5] 10.3 [Ref] 20.1 [27.4] 
   ≥80% 74,844 (66.1) 0.0 [271.5] 78.7 [Ref] 79.9 [3.1] 
Percentages are column percentages. *Enrolled in Medicare and Medicaid. †Median household income of US 
Census block groups for individuals aged 65 and older. ‡Medicare Chronic Condition Data Warehouse definition. 
§Primary care physician, physician assistant, or nurse practitioner. ǁWeighted average of the simvastatin-equivalent 
average daily dose in the post-AMI period minus the weighted average of the pre-AMI period. #According to the 
2013 American College of Cardiology/ American Heart Association guidelines on the reduction of atherosclerotic 
cardiovascular risk. Abbreviations: AMI=acute myocardial infarction; PDC=proportion of days covered; 
ASD=absolute standardized difference; Ref=reference group for ASD calculation; SD=standard deviation; 
CCI=Charlson Comorbidity Index; CeVD=cerebrovascular disease; CHF=congestive heart failure; COPD=chronic 
obstructive pulmonary disease; PVD=peripheral vascular disease; CCW=Alz=Alzheimer’s disease; 
CABG=Coronary artery bypass surgery; PTCA=percutaneous transluminal coronary angioplasty; IHD=ischemic 
heart disease; ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker; 
subend=subendocardial; Rhabdo=rhabdomyolysis; Cardiac cath=cardiac catheterization; CCU=coronary care unit; 
ICU=intensive care unit; PCP=primary care provider; ADD=average daily dose. 
Table S2. Patient characteristics stratified by pre-AMI statin adherence. 
  Pre-AMI PDC 
 <40% 40-79.9% ≥80% 
 N=18,205 N=24,373 N=70,718 
Patient Characteristics % [ASD] % [ASD] % [ASD] 
Age    
   Mean ± SD 76.7 ± 7.3 [12.0] 76.9 ± 7.2 [9.5] 77.6 ± 7.4 [Ref] 
   66-75 48.7 [11.0] 47.3 [8.2] 43.3 [Ref] 
   76-85 37.7 [5.0] 39.0 [2.3] 40.1 [Ref] 
   86+ 13.6 [8.5] 13.7 [8.2] 16.6 [Ref] 
Female 55.6 [4.0] 55.4 [3.6] 53.6 [Ref] 
Race/ethnicity    
   White 80.0 [17.1] 81.5 [13.3] 86.3 [Ref] 
   Black 12.2 [17.9] 10.6 [13.1] 6.9 [Ref] 
   Hispanic 3.9 [7.4] 3.6 [6.2] 2.6 [Ref] 
   Asian 2.1 [1.2] 2.1 [0.9] 2.3 [Ref] 
   Other 1.9 [0.3] 2.1 [1.7] 1.9 [Ref] 
Dual eligibility* 25.6 [1.4] 25.0 [0.0] 25.0 [Ref] 
Household income†    
   ≤$30,000 49.4 [6.1] 47.6 [2.4] 46.4 [Ref] 
   $30,001-60,000 40.0 [3.6] 40.9 [1.6] 41.7 [Ref] 
   $60,001-100,000 8.7 [2.9] 9.3 [0.8] 9.5 [Ref] 
   $100,001-150,000 1.5 [2.7] 1.7 [1.1] 1.8 [Ref] 
   >$150,000 0.5 [1.4] 0.6 [0.0] 0.6 [Ref] 
CCI comorbidities    
   AMI 5.2 [3.0] 4.5 [0.2] 4.5 [Ref] 
   Cancer 12.1 [0.4] 12.2 [0.1] 12.2 [Ref] 
   CeVD 18.5 [0.5] 18.9 [1.6] 18.3 [Ref] 
   CHF 29.5 [2.4] 30.0 [1.2] 30.6 [Ref] 
   COPD 29.2 [4.1] 27.7 [0.7] 27.4 [Ref] 
   Dementia 3.2 [2.5] 3.1 [1.7] 2.8 [Ref] 
   Diabetes 47.1 [1.9] 47.7 [0.9] 48.1 [Ref] 
   Liver disease 2.2 [3.4] 2.2 [3.3] 1.7 [Ref] 
   Metastatic cancer 1.8 [3.4] 1.7 [2.4] 1.4 [Ref] 
   Para-/hemiplagia 1.2 [1.1] 1.1 [0.7] 1.1 [Ref] 
   Peptic ulcer disease 2.0 [2.8] 2.0 [2.7] 1.6 [Ref] 
   PVD 23.6 [0.5] 23.5 [0.1] 23.4 [Ref] 
   Renal disease 18.4 [2.6] 18.6 [2.1] 19.4 [Ref] 
   Rheumatic disease 4.0 [1.7] 3.8 [0.6] 3.6 [Ref] 
    
    
  Pre-AMI PDC 
 <40% 40-79.9% ≥80% 
 N=18,205 N=24,373 N=70,718 
Patient Characteristics % [ASD] % [ASD] % [ASD] 
CCI    
   Mean ± SD 2.5 ± 2.4 [0.9] 2.5 ± 2.4 [0.5] 2.5 ± 2.3 [Ref] 
   0 20.2 [1.0] 20.3 [1.2] 19.8 [Ref] 
   1-2 38.2 [0.6] 38.5 [0.0] 38.5 [Ref] 
   3-5 30.5 [1.4] 30.2 [2.0] 31.1 [Ref] 
   6-8 8.7 [0.1] 8.8 [0.2] 8.7 [Ref] 
   9 or more 2.4 [3.6] 2.3 [2.5] 1.9 [Ref] 
Other comorbidities    
   Dementia/Alz‡ 10.3 [0.5] 10.5 [1.2] 10.1 [Ref] 
   Depression 15.7 [1.6] 16.0 [2.4] 15.1 [Ref] 
   CABG 0.9 [1.6] 1.1 [0.4] 1.0 [Ref] 
   PTCA/stent 7.0 [2.0] 6.6 [0.6] 6.5 [Ref] 
   IHD 58.7 [5.0] 60.7 [0.9] 61.1 [Ref] 
   Unstable angina 5.5 [0.6] 5.4 [0.0] 5.4 [Ref] 
   Lipid abnormalities 87.5 [7.0] 89.9 [0.6] 89.7 [Ref] 
   Rhabdo/myopathy 7.9 [6.9] 7.1 [3.9] 6.2 [Ref] 
Pre-AMI medications    
   Beta-blocker 57.8 [19.1] 63.6 [7.2] 67.0 [Ref] 
   ACE inhibitor/ARB 60.2 [17.0] 66.5 [3.9] 68.3 [Ref] 
Index admission    
   Subend infarction 78.1 [5.8] 78.7 [4.3] 80.4 [Ref] 
   CABG 6.4 [1.3] 6.3 [0.9] 6.1 [Ref] 
   PTCA/stent 39.3 [7.5] 37.8 [4.4] 35.7 [Ref] 
   Platelet inhibitors 4.7 [2.6] 4.5 [1.6] 4.2 [Ref] 
   Cardiac cath 60.2 [8.2] 58.8 [5.5] 56.1 [Ref] 
   Angiocardiography 59.5 [6.1] 58.9 [5.0] 56.4 [Ref] 
   Cardiogenic shock 2.1 [0.0] 2.4 [1.8] 2.1 [Ref] 
   Dysrhythmias 30.2 [3.8] 29.9 [4.5] 31.9 [Ref] 
   Hypotension 4.8 [1.2] 5.1 [0.2] 5.0 [Ref] 
   Acute renal failure 15.1 [2.5] 15.7 [0.8] 16.0 [Ref] 
   Heart failure 38.7 [4.6] 39.5 [2.9] 41.0 [Ref] 
   Length of stay (days)    
      Mean ± SD 5.3 ± 5.1 [0.7] 5.3 ± 4.9 [0.5] 5.3 ± 5.0 [Ref] 
      1-3 44.3 [1.0] 44.6 [1.7] 43.8 [Ref] 
      4-6 31.4 [0.6] 30.7 [0.9] 31.1 [Ref] 
      7-11 16.7 [2.1] 16.8 [2.0] 17.5 [Ref] 
      12+ 7.7 [0.2] 7.9 [1.2] 7.6 [Ref] 
  Pre-AMI PDC 
 <40% 40-79.9% ≥80% 
 N=18,205 N=24,373 N=70,718 
Patient Characteristics % [ASD] % [ASD] % [ASD] 
   Intensive care    
      None 24.2 [3.4] 25.0 [1.4] 25.7 [Ref] 
      CCU only 24.2 [3.1] 23.4 [1.2] 22.9 [Ref] 
      ICU only 40.8 [1.1] 40.7 [1.3] 41.4 [Ref] 
      Both 10.8 [2.3] 10.8 [2.4] 10.1 [Ref] 
   Cardiologist consult 86.7 [1.1] 86.7 [1.1] 86.3 [Ref] 
30-day follow-up    
   None 17.0 [6.7] 15.7 [3.3] 14.5 [Ref] 
   PCP only§ 29.6 [0.4] 29.4 [0.0] 29.4 [Ref] 
   Cardiologist only 17.7 [0.3] 18.2 [1.0] 17.8 [Ref] 
   Both 35.8 [5.1] 36.7 [3.3] 38.2 [Ref] 
Simvastatin ADD changeǁ -4.0 ± 43.8 [23.3] 2.1 ± 36.0 [8.0] 4.7 ± 30.4 [Ref] 
Pre-AMI statin#    
   Low intensity 11.4 [1.7] 9.7 [4.0] 11.0 [Ref] 
   Moderate intensity 66.9 [3.4] 66.9 [3.3] 68.5 [Ref] 
   High intensity 21.6 [2.6] 23.3 [6.6] 20.6 [Ref] 
Post-AMI statin#    
   Low intensity 8.7 [0.7] 7.7 [3.0] 8.5 [Ref] 
   Moderate intensity 63.8 [2.4] 62.9 [4.2] 65.0 [Ref] 
   High intensity 27.5 [2.1] 29.4 [6.3] 26.6 [Ref] 
Post-AMI PDC    
   <40% 43.8 [96.9] 19.8 [41.7] 6.1 [Ref] 
   40-79.9% 24.6 [29.3] 30.7 [43.2] 13.3 [Ref] 
   ≥80% 31.6 [113.8] 49.5 [69.2] 80.7 [Ref] 
Percentages are column percentages. *Enrolled in Medicare and Medicaid. †Median household income of 
US Census block groups for individuals aged 65 and older. ‡Medicare Chronic Condition Data Warehouse 
definition. §Primary care physician, physician assistant, or nurse practitioner. ǁWeighted average of the 
simvastatin-equivalent average daily dose in the post-AMI period minus the weighted average of the pre-
AMI period. #According to the 2013 American College of Cardiology/ American Heart Association 
guidelines on the reduction of atherosclerotic cardiovascular risk. Abbreviations: AMI=acute myocardial 
infarction; PDC=proportion of days covered; ASD=absolute standardized difference; Ref=reference group 
for ASD calculation; SD=standard deviation; CCI=Charlson Comorbidity Index; CeVD=cerebrovascular 
disease; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; PVD=peripheral 
vascular disease; CCW=Alz=Alzheimer’s disease; CABG=Coronary artery bypass surgery; 
PTCA=percutaneous transluminal coronary angioplasty; IHD=ischemic heart disease; ACE=angiotensin-
converting enzyme; ARB=angiotensin II receptor blocker; subend=subendocardial; 
Rhabdo=rhabdomyolysis; Cardiac cath=cardiac catheterization; CCU=coronary care unit; ICU=intensive 
care unit; PCP=primary care provider; ADD=average daily dose. 
 
 
 
Table S3. Patient characteristics stratified by post-AMI statin adherence. 
  Post-AMI PDC 
 <40% 40-79.9% ≥80% 
 N=17,104 N=21,348 N=74,844 
Patient Characteristics % [ASD] % [ASD] % [ASD] 
Age    
   Mean ± SD 77.5 ± 7.5 [3.1] 77.0 ± 7.3 [4.6] 77.3 ± 7.3 [Ref] 
   66-75 44.1 [1.3] 46.8 [4.2] 44.7 [Ref] 
   76-85 39.2 [1.1] 38.8 [1.9] 39.8 [Ref] 
   86+ 16.7 [3.2] 14.3 [3.3] 15.5 [Ref] 
Female 55.5 [3.4] 55.1 [2.6] 53.8 [Ref] 
Race/ethnicity    
   White 82.2 [8.7] 82.0 [9.2] 85.4 [Ref] 
   Black 10.9 [11.9] 10.4 [10.0] 7.5 [Ref] 
   Hispanic 3.3 [2.8] 3.5 [3.8] 2.8 [Ref] 
   Asian 1.7 [4.7] 2.0 [2.4] 2.4 [Ref] 
   Other 1.9 [0.2] 2.1 [1.6] 1.9 [Ref] 
Dual eligibility* 23.6 [5.2] 24.0 [4.1] 25.8 [Ref] 
Household income†    
   ≤$30,000 48.7 [4.2] 47.7 [2.3] 46.6 [Ref] 
   $30,001-60,000 40.7 [1.7] 40.7 [1.7] 41.6 [Ref] 
   $60,001-100,000 8.6 [3.0] 9.4 [0.5] 9.5 [Ref] 
   $100,001-150,000 1.5 [2.0] 1.7 [0.4] 1.8 [Ref] 
   >$150,000 0.5 [1.3] 0.5 [1.6] 0.6 [Ref] 
CCI comorbidities    
   AMI 6.2 [8.8] 4.6 [1.9] 4.2 [Ref] 
   Cancer 13.4 [4.8] 12.3 [1.5] 11.8 [Ref] 
   CeVD 20.6 [7.2] 19.1 [3.4] 17.8 [Ref] 
   CHF 35.9 [14.8] 30.5 [3.4] 29.0 [Ref] 
   COPD 31.7 [10.7] 28.0 [2.7] 26.8 [Ref] 
   Dementia 4.1 [8.2] 2.9 [1.6] 2.6 [Ref] 
   Diabetes 49.1 [3.5] 48.5 [2.2] 47.4 [Ref] 
   Liver disease 2.6 [6.3] 2.0 [1.9] 1.7 [Ref] 
   Metastatic cancer 2.3 [7.8] 1.5 [2.1] 1.3 [Ref] 
   Para-/hemiplagia 1.4 [3.0] 1.0 [0.4] 1.0 [Ref] 
   Peptic ulcer disease 2.1 [3.4] 1.9 [1.7] 1.6 [Ref] 
   PVD 26.5 [9.0] 23.9 [3.1] 22.6 [Ref] 
   Renal disease 21.5 [7.5] 18.9 [0.9] 18.5 [Ref] 
   Rheumatic disease 4.3 [3.3] 3.6 [0.1] 3.6 [Ref] 
    
    
  Post-AMI PDC 
 <40% 40-79.9% ≥80% 
 N=17,104 N=21,348 N=74,844 
Patient Characteristics % [ASD] % [ASD] % [ASD] 
CCI    
   Mean ± SD 2.9 ± 2.5 [18.1] 2.6 ± 2.3 [5.0] 2.4 ± 2.3 [Ref] 
   0 16.3 [11.8] 19.5 [3.6] 20.9 [Ref] 
   1-2 36.0 [6.2] 38.2 [1.7] 39.0 [Ref] 
   3-5 33.6 [7.7] 31.6 [3.4] 30.0 [Ref] 
   6-8 10.9 [9.3] 8.6 [1.5] 8.2 [Ref] 
   9 or more 3.1 [8.3] 2.1 [2.2] 1.8 [Ref] 
Other comorbidities    
   Dementia/Alz‡ 12.5 [8.9] 10.3 [2.3] 9.7 [Ref] 
   Depression 17.2 [6.6] 16.2 [3.8] 14.8 [Ref] 
   CABG 1.0 [0.5] 1.0 [0.2] 1.0 [Ref] 
   PTCA/stent 8.0 [7.2] 6.9 [3.0] 6.2 [Ref] 
   IHD 65.5 [13.1] 61.7 [5.2] 59.2 [Ref] 
   Unstable angina 6.4 [5.6] 5.6 [2.5] 5.1 [Ref] 
   Lipid abnormalities 88.6 [3.1] 89.7 [0.5] 89.5 [Ref] 
   Rhabdo/myopathy 8.3 [8.6] 7.2 [4.4] 6.1 [Ref] 
Pre-AMI medications    
   Beta-blocker 62.9 [5.5] 63.9 [3.2] 65.5 [Ref] 
   ACE inhibitor/ARB 62.9 [9.9] 66.2 [3.0] 67.6 [Ref] 
Index admission    
   Subend infarction 81.4 [5.7] 80.3 [2.7] 79.2 [Ref] 
   CABG 4.6 [8.7] 6.1 [1.8] 6.5 [Ref] 
   PTCA/stent 30.1 [17.6] 36.0 [5.1] 38.4 [Ref] 
   Platelet inhibitors 3.8 [3.4] 4.2 [1.3] 4.5 [Ref] 
   Cardiac cath 50.8 [16.0] 57.7 [2.2] 58.7 [Ref] 
   Angiocardiography 50.8 [16.3] 57.6 [2.7] 58.9 [Ref] 
   Cardiogenic shock 1.9 [2.5] 2.1 [1.0] 2.3 [Ref] 
   Dysrhythmias 31.4 [0.1] 30.6 [1.7] 31.4 [Ref] 
   Hypotension 5.0 [0.5] 4.8 [1.1] 5.1 [Ref] 
   Acute renal failure 17.0 [4.3] 15.9 [1.4] 15.4 [Ref] 
   Heart failure 43.3 [7.0] 39.6 [0.5] 39.8 [Ref] 
   Length of stay (days)    
      Mean ± SD 5.6 ± 5.8 [6.7] 5.3 ± 5.0 [1.5] 5.2 ± 4.8 [Ref] 
      1-3 41.2 [6.8] 44.3 [0.5] 44.6 [Ref] 
      4-6 32.1 [2.6] 30.9 [0.1] 30.9 [Ref] 
      7-11 18.2 [3.1] 17.1 [0.0] 17.1 [Ref] 
      12+ 8.5 [3.7] 7.7 [0.7] 7.5 [Ref] 
  Post-AMI PDC 
 <40% 40-79.9% ≥80% 
 N=17,104 N=21,348 N=74,844 
Patient Characteristics % [ASD] % [ASD] % [ASD] 
   Intensive care    
      None 26.3 [2.7] 24.9 [0.6] 25.2 [Ref] 
      CCU only 22.4 [2.2] 23.3 [0.0] 23.3 [Ref] 
      ICU only 41.4 [0.8] 41.3 [0.5] 41.1 [Ref] 
      Both 9.8 [2.1] 10.5 [0.2] 10.4 [Ref] 
   Cardiologist consult 84.8 [5.8] 86.6 [0.7] 86.8 [Ref] 
30-day follow-up    
   None 17.8 [9.2] 15.6 [3.1] 14.4 [Ref] 
   PCP only§ 32.1 [7.4] 29.8 [2.5] 28.7 [Ref] 
   Cardiologist only 15.7 [7.0] 18.0 [1.0] 18.4 [Ref] 
   Both 34.3 [8.6] 36.6 [3.9] 38.5 [Ref] 
Simvastatin ADD changeǁ -20.7 ± 41.0 [78.4] 3.7 ± 31.0 [13.1] 7.8 ± 31.1 [Ref] 
Pre-AMI statin#    
   Low intensity 11.5 [1.2] 9.0 [7.0] 11.1 [Ref] 
   Moderate intensity 66.9 [3.7] 66.1 [5.4] 68.6 [Ref] 
   High intensity 21.6 [3.4] 24.9 [11.1] 20.3 [Ref] 
Post-AMI statin#    
   Low intensity 10.5 [8.4] 7.4 [2.4] 8.1 [Ref] 
   Moderate intensity 66.0 [3.5] 63.1 [2.7] 64.3 [Ref] 
   High intensity 23.5 [9.4] 29.5 [4.2] 27.6 [Ref] 
Pre-AMI PDC    
   <40% 46.6 [97.5] 21.0 [38.7] 7.7 [Ref] 
   40-79.9% 28.2 [29.4] 35.1 [44.6] 16.1 [Ref] 
   ≥80% 25.2 [118.8] 43.9 [69.8] 76.2 [Ref] 
Percentages are column percentages. *Enrolled in Medicare and Medicaid. †Median household income of 
US Census block groups for individuals aged 65 and older. ‡Medicare Chronic Condition Data Warehouse 
definition. §Primary care physician, physician assistant, or nurse practitioner. ǁWeighted average of the 
simvastatin-equivalent average daily dose in the post-AMI period minus the weighted average of the pre-
AMI period. #According to the 2013 American College of Cardiology/ American Heart Association 
guidelines on the reduction of atherosclerotic cardiovascular risk. Abbreviations: AMI=acute myocardial 
infarction; PDC=proportion of days covered; ASD=absolute standardized difference; Ref=reference group 
for ASD calculation; SD=standard deviation; CCI=Charlson Comorbidity Index; CeVD=cerebrovascular 
disease; CHF=congestive heart failure; COPD=chronic obstructive pulmonary disease; PVD=peripheral 
vascular disease; CCW=Alz=Alzheimer’s disease; CABG=Coronary artery bypass surgery; 
PTCA=percutaneous transluminal coronary angioplasty; IHD=ischemic heart disease; ACE=angiotensin-
converting enzyme; ARB=angiotensin II receptor blocker; subend=subendocardial; 
Rhabdo=rhabdomyolysis; Cardiac cath=cardiac catheterization; CCU=coronary care unit; ICU=intensive 
care unit; PCP=primary care provider; ADD=average daily dose. 
 
 
 
Table S4. Full model for 3-level multinomial regression model predicting statin adherence 
change after an AMI. 
  Model 1: 3-Level Multinomial 
 Logistic Regression* 
 OR (99% CI) 
Patient Characteristics Decrease Increase 
Pre-AMI PDC (10%)† 1.04 (1.03, 1.05) 0.67 (0.67, 0.68) 
Age   
   66-75 1. 1. 
   76-85 0.99 (0.94, 1.04) 0.97 (0.92, 1.02) 
   86+ 0.99 (0.92, 1.06) 0.88 (0.81, 0.95) 
Female 1.03 (0.98, 1.08) 1.06 (1.01, 1.12) 
Race/ethnicity   
   White 1. 1. 
   Black 1.21 (1.12, 1.31) 1.14 (1.05, 1.23) 
   Hispanic 1.30 (1.15, 1.48) 1.29 (1.13, 1.48) 
   Asian 0.97 (0.83, 1.14) 1.16 (0.99, 1.36) 
   Other 1.22 (1.05, 1.42) 1.15 (0.97, 1.36) 
Dual eligibility‡ 0.80 (0.75, 0.84) 1.18 (1.11, 1.25) 
Household income§   
   ≤$30,000 1. 1. 
   $30,001-60,000 0.96 (0.91, 1.00) 0.98 (0.93, 1.03) 
   $60,001-100,000 0.96 (0.89, 1.04) 1.03 (0.95, 1.12) 
   $100,001-150,000 1.01 (0.86, 1.19) 1.05 (0.87, 1.26) 
   >$150,000 0.79 (0.58, 1.08) 1.10 (0.80, 1.51) 
Adjusted CCIǁ   
   0 1. 1. 
   1-2 1.03 (0.97, 1.10) 0.88 (0.83, 0.94) 
   3-5 1.08 (1.01, 1.15) 0.84 (0.79, 0.91) 
   6-8 1.14 (1.04, 1.26) 0.81 (0.73, 0.91) 
   9 or more 1.39 (1.19, 1.62) 0.77 (0.64, 0.93) 
Baseline comorbidities   
   Prior AMI# 1.04 (0.94, 1.15) 0.92 (0.81, 1.04) 
   Dementia/Alz** 1.13 (1.06, 1.21) 1.05 (0.97, 1.14) 
   Depression 1.11 (1.05, 1.18) 1.02 (0.95, 1.09) 
   CABG 1.13 (0.92, 1.39) 1.28 (1.01, 1.62) 
   PTCA/stent 1.12 (1.02, 1.23) 0.85 (0.76, 0.95) 
   Ischemic heart disease 1.09 (1.04, 1.15) 0.84 (0.79, 0.89) 
   Unstable angina 1.04 (0.94, 1.15) 0.89 (0.79, 1.00) 
   Lipid abnormalities 1.00 (0.93, 1.07) 1.07 (0.99, 1.16) 
   Rhabdomyolysis/myopathy 1.15 (1.05, 1.24) 1.01 (0.92, 1.11) 
  Model 1: 3-Level Multinomial 
 Logistic Regression* 
 OR (99% CI) 
Patient Characteristics Decrease Increase 
Concurrent medications   
   Beta-blocker 0.88 (0.84, 0.93) 0.99 (0.94, 1.04) 
   ACE inhibitor/ARB 0.95 (0.91, 1.00) 1.10 (1.05, 1.16) 
Index admission   
   Subendocardial infarction†† 0.97 (0.92, 1.03) 0.90 (0.85, 0.96) 
   CABG 0.78 (0.71, 0.87) 1.34 (1.21, 1.49) 
   PTCA/stent 0.82 (0.78, 0.87) 1.25 (1.17, 1.32) 
   Platelet inhibitors 0.91 (0.81, 1.02) 1.00 (0.89, 1.12) 
   Cardiac catheterization 1.03 (0.95, 1.12) 1.09 (1.00, 1.19) 
   Angiocardiography 0.90 (0.82, 0.97) 1.05 (0.97, 1.15) 
   Cardiogenic shock 1.04 (0.90, 1.21) 1.14 (0.98, 1.34) 
   Cardiac dysrhythmias 1.00 (0.95, 1.05) 0.93 (0.88, 0.98) 
   Hypotension 1.01 (0.91, 1.11) 1.05 (0.94, 1.16) 
   Acute renal failure 1.05 (0.99, 1.12) 1.00 (0.93, 1.07) 
   Heart failure 1.02 (0.98, 1.07) 1.00 (0.95, 1.06) 
   Length of stay (days)   
      1-3 1. 1. 
      4-6 1.05 (1.00, 1.11) 1.00 (0.94, 1.06) 
      7-11 1.14 (1.07, 1.22) 1.02 (0.95, 1.10) 
      12+ 1.27 (1.16, 1.39) 1.08 (0.97, 1.20) 
   Intensive care   
      None 1. 1. 
      Coronary care unit only 1.03 (0.96, 1.09) 1.03 (0.96, 1.11) 
      Intensive care unit only 1.05 (1.00, 1.11) 1.01 (0.95, 1.07) 
      Both 1.04 (0.96, 1.13) 1.03 (0.94, 1.12) 
   Cardiologist consult 0.95 (0.89, 1.01) 1.04 (0.96, 1.11) 
30-day follow-up   
   None 1. 1. 
   PCP only‡‡ 0.97 (0.91, 1.04) 1.08 (1.00, 1.16) 
   Cardiologist only 0.91 (0.84, 0.98) 1.15 (1.05, 1.25) 
   Both 0.95 (0.89, 1.02) 1.21 (1.12, 1.30) 
*Three-level multinomial logistic regression comparing decrease in adherence to no change and comparing 
increase in adherence to no change. †Odds ratio for a 10% higher pre-AMI adherence (e.g. 50% compared 
to 40%). ‡Enrolled in Medicare and Medicaid. §Median household income of US Census block groups for 
individuals aged 65 and older. ǁCCI score does not include counts for AMI and dementia. #CCI definition. 
**Medicare Chronic Condition Data Warehouse definition. ††Diagnosis code for subendocardial 
infarction, compared to a transmural infarction. ‡‡Primary care physician, physician assistant, or nurse 
practitioner. Abbreviations: AMI=acute myocardial infarction; OR=odds ratio; CI=confidence interval; 
PDC=proportion of days covered; CCI=Charlson Comorbidity Index; Alz=Alzheimer’s disease; 
CABG=Coronary artery bypass surgery; PTCA=percutaneous transluminal coronary angioplasty; 
ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker; PCP=primary care provider. 
Table S5. Full model for five-level multinomial regression model predicting statin adherence change after an AMI. 
  Model 2: 5-Level Multinomial Logistic Regression* 
 OR (99% CI) OR (99% CI) OR (99% CI) OR (99% CI) 
Patient Characteristics Major Decrease Mild/Moderate Decrease Mild/Moderate Increase Major Increase 
Pre-AMI PDC (10%)‡‡ 1.48 (1.43, 1.54) 0.99 (0.98, 1.00) 0.71 (0.71, 0.72) 0.49 (0.48, 0.49) 
Age     
   66-75 1. 1. 1. 1. 
   76-85 0.95 (0.87, 1.05) 1.00 (0.95, 1.06) 0.96 (0.91, 1.02) 1.01 (0.92, 1.11) 
   86+ 0.99 (0.88, 1.12) 0.98 (0.91, 1.06) 0.86 (0.79, 0.93) 0.94 (0.81, 1.08) 
Female 1.06 (0.97, 1.15) 1.02 (0.97, 1.07) 1.07 (1.01, 1.12) 1.04 (0.95, 1.14) 
Race/ethnicity     
   White 1. 1. 1. 1. 
   Black 1.25 (1.07, 1.45) 1.21 (1.11, 1.32) 1.15 (1.06, 1.25) 1.16 (1.01, 1.34) 
   Hispanic 1.29 (1.00, 1.64) 1.32 (1.15, 1.52) 1.32 (1.15, 1.51) 1.25 (1.00, 1.58) 
   Asian 0.87 (0.64, 1.19) 1.01 (0.84, 1.20) 1.18 (1.00, 1.39) 1.09 (0.82, 1.47) 
   Other 1.19 (0.88, 1.59) 1.24 (1.04, 1.46) 1.14 (0.96, 1.36) 1.27 (0.94, 1.71) 
Dual eligibility† 0.81 (0.73, 0.90) 0.79 (0.74, 0.84) 1.13 (1.06, 1.20) 1.46 (1.31, 1.63) 
Household income‡     
   ≤$30,000 1. 1. 1. 1. 
   $30,001-60,000 0.95 (0.87, 1.04) 0.96 (0.91, 1.01) 0.98 (0.93, 1.04) 0.99 (0.90, 1.08) 
   $60,001-100,000 0.95 (0.82, 1.11) 0.96 (0.88, 1.05) 1.03 (0.95, 1.13) 1.05 (0.89, 1.22) 
   $100,001-150,000 0.91 (0.66, 1.25) 1.04 (0.87, 1.25) 1.03 (0.85, 1.25) 1.16 (0.82, 1.63) 
   >$150,000 0.81 (0.45, 1.45) 0.79 (0.56, 1.11) 1.13 (0.82, 1.56) 0.90 (0.47, 1.70) 
Adjusted CCI§     
   0 1. 1. 1. 1. 
   1-2 1.01 (0.90, 1.14) 1.04 (0.97, 1.11) 0.89 (0.83, 0.95) 0.82 (0.73, 0.92) 
   3-5 1.07 (0.94, 1.22) 1.08 (1.00, 1.17) 0.87 (0.81, 0.94) 0.69 (0.61, 0.79) 
   6-8 1.15 (0.96, 1.37) 1.14 (1.02, 1.27) 0.82 (0.73, 0.92) 0.74 (0.61, 0.91) 
   9 or more 1.37 (1.02, 1.83) 1.40 (1.18, 1.66) 0.81 (0.66, 0.99) 0.58 (0.41, 0.83) 
  Model 2: 5-Level Multinomial Logistic Regression* 
 OR (99% CI) OR (99% CI) OR (99% CI) OR (99% CI) 
Patient Characteristics Major Decrease Mild/Moderate Decrease Mild/Moderate Increase Major Increase 
Baseline comorbidities     
   Prior AMIǁ 1.14 (0.95, 1.38) 1.01 (0.90, 1.13) 0.92 (0.81, 1.05) 0.90 (0.72, 1.14) 
   Dementia/Alz# 1.30 (1.15, 1.47) 1.08 (1.00, 1.17) 1.06 (0.97, 1.15) 0.97 (0.83, 1.14) 
   Depression 1.14 (1.02, 1.28) 1.10 (1.03, 1.18) 1.01 (0.94, 1.09) 1.03 (0.91, 1.16) 
   CABG 1.24 (0.84, 1.83) 1.10 (0.87, 1.38) 1.26 (0.99, 1.61) 1.35 (0.85, 2.17) 
   PTCA/stent 1.21 (1.02, 1.45) 1.09 (0.99, 1.21) 0.86 (0.77, 0.96) 0.79 (0.64, 0.97) 
   Ischemic heart disease 1.07 (0.97, 1.18) 1.10 (1.04, 1.17) 0.89 (0.84, 0.94) 0.61 (0.56, 0.68) 
   Unstable angina 1.01 (0.84, 1.22) 1.05 (0.94, 1.17) 0.87 (0.77, 0.99) 0.97 (0.78, 1.20) 
   Lipid abnormalities 0.88 (0.77, 1.01) 1.04 (0.96, 1.13) 1.08 (1.00, 1.18) 1.07 (0.94, 1.23) 
   Rhabdo/myopathy 1.15 (0.98, 1.35) 1.15 (1.04, 1.26) 1.03 (0.94, 1.14) 0.91 (0.77, 1.08) 
Concurrent medications     
   Beta-blocker 0.83 (0.75, 0.91) 0.90 (0.85, 0.95) 0.99 (0.94, 1.04) 1.01 (0.92, 1.11) 
   ACE inhibitor/ARB 0.88 (0.81, 0.97) 0.98 (0.93, 1.03) 1.09 (1.04, 1.15) 1.19 (1.09, 1.31) 
Index admission     
   Subend infarction** 0.91 (0.82, 1.02) 0.99 (0.93, 1.06) 0.92 (0.86, 0.98) 0.81 (0.73, 0.90) 
   CABG 0.73 (0.59, 0.89) 0.80 (0.71, 0.91) 1.28 (1.15, 1.43) 1.77 (1.46, 2.14) 
   PTCA/stent 0.80 (0.72, 0.89) 0.83 (0.78, 0.88) 1.19 (1.12, 1.27) 1.60 (1.43, 1.78) 
   Platelet inhibitors 0.86 (0.68, 1.09) 0.92 (0.81, 1.05) 1.01 (0.90, 1.13) 0.95 (0.78, 1.16) 
   Cardiac catheterization 0.99 (0.84, 1.17) 1.04 (0.95, 1.15) 1.07 (0.97, 1.17) 1.20 (1.02, 1.41) 
   Angiocardiography 0.87 (0.74, 1.02) 0.91 (0.83, 0.99) 1.06 (0.97, 1.16) 1.02 (0.87, 1.19) 
   Cardiogenic shock 0.87 (0.64, 1.17) 1.10 (0.94, 1.30) 1.14 (0.97, 1.34) 1.21 (0.92, 1.60) 
   Cardiac dysrhythmias 1.01 (0.92, 1.10) 0.99 (0.94, 1.05) 0.93 (0.88, 0.98) 0.90 (0.82, 0.99) 
   Hypotension 1.01 (0.84, 1.22) 1.01 (0.90, 1.12) 1.05 (0.94, 1.17) 1.04 (0.86, 1.27) 
   Acute renal failure 1.05 (0.94, 1.17) 1.05 (0.98, 1.13) 1.00 (0.93, 1.07) 0.99 (0.87, 1.13) 
   Heart failure 1.08 (0.99, 1.18) 1.00 (0.95, 1.06) 1.00 (0.95, 1.06) 1.00 (0.91, 1.10) 
   Length of stay (days)     
  Model 2: 5-Level Multinomial Logistic Regression* 
 OR (99% CI) OR (99% CI) OR (99% CI) OR (99% CI) 
Patient Characteristics Major Decrease Mild/Moderate Decrease Mild/Moderate Increase Major Increase 
      1-3 1. 1. 1. 1. 
      4-6 1.11 (1.01, 1.23) 1.04 (0.98, 1.10) 0.99 (0.93, 1.05) 1.04 (0.94, 1.16) 
      7-11 1.36 (1.21, 1.53) 1.08 (1.01, 1.17) 1.00 (0.93, 1.08) 1.10 (0.96, 1.25) 
      12+ 1.67 (1.42, 1.96) 1.16 (1.05, 1.28) 1.07 (0.96, 1.19) 1.11 (0.91, 1.34) 
   Intensive care     
      None 1. 1. 1. 1. 
      CCU only 1.03 (0.91, 1.16) 1.03 (0.96, 1.10) 1.02 (0.95, 1.09) 1.12 (0.98, 1.27) 
      ICU only 1.09 (0.98, 1.21) 1.04 (0.98, 1.11) 1.00 (0.94, 1.06) 1.07 (0.95, 1.20) 
      Both 1.00 (0.85, 1.18) 1.05 (0.96, 1.16) 1.02 (0.92, 1.12) 1.09 (0.93, 1.29) 
   Cardiologist consult 0.95 (0.84, 1.08) 0.95 (0.88, 1.02) 1.02 (0.94, 1.10) 1.14 (0.99, 1.31) 
30-day follow-up     
   None 1. 1. 1. 1. 
   PCP only†† 1.01 (0.89, 1.15) 0.96 (0.89, 1.03) 1.07 (0.99, 1.15) 1.10 (0.96, 1.27) 
   Cardiologist only 0.83 (0.72, 0.97) 0.93 (0.85, 1.01) 1.13 (1.03, 1.23) 1.27 (1.09, 1.48) 
   Both 0.93 (0.82, 1.06) 0.95 (0.89, 1.03) 1.16 (1.08, 1.26) 1.48 (1.29, 1.69) 
*Five-level multinomial logistic regression model comparing all four outcomes in table to the reference group of no change in adherence. †Enrolled 
in Medicare and Medicaid. ‡Median household income of US Census block groups for individuals aged 65 and older. §CCI score does not include 
counts for AMI and dementia. ǁCCI definition. #Medicare Chronic Condition Data Warehouse definition. **Diagnosis code for subendocardial 
infarction, compared to a transmural infarction. ††Primary care physician, physician assistant, or nurse practitioner. ‡‡Odds ratio for a 10% higher 
pre-AMI adherence (e.g. 50% compared to 40%). Abbreviations: AMI=acute myocardial infarction; OR=odds ratio; CI=confidence interval; 
PDC=proportion of days covered; CCI=Charlson Comorbidity Index; Alz=Alzheimer’s disease; CABG=Coronary artery bypass surgery; 
PTCA=percutaneous transluminal coronary angioplasty; Rhabdo=rhabdomyolysis; ACE=angiotensin-converting enzyme; ARB=angiotensin II 
receptor blocker; subend=subendocardial; CCU=coronary care unit; ICU=intensive care unit; PCP=primary care provider. 
 
 
Table S6. Crude estimates, fully adjusted model, and sensitivity analyses involving changing variable definitions or adding new 
variables to the model for the three-level multinomial regression model predicting statin adherence change after an AMI. 
    
Crude 
estimates 
Crude + 
pre-AMI 
PDC† 
Fully 
adjusted 
model‡ 
Adherence 
change 
conservative§ 
6-week 
follow-upǁ 
Liver 
disease# 
ADD 
change** 
Statin 
intensity†† 
 Patient characteristics   OR [99% CLR] 
Pre-AMI PDC (10%)‡‡ 
Increase 0.67 [1.01]  0.67 [1.01] 0.67 [1.01] 0.67 [1.01] 0.67 [1.01] 0.66 [1.02]* 0.67 [1.01] 
Decrease 1.03 [1.02]  1.04 [1.02] 1.05 [1.02] 1.04 [1.02] 1.04 [1.02] 1.08 [1.02]* 1.04 [1.02] 
Age          
   66-75  1. 1. 1. 1. 1. 1. 1. 1. 
   76-85 
Increase 0.87 [1.09]* 0.92 [1.11] 0.97 [1.11] 0.97 [1.11] 0.97 [1.11] 0.97 [1.11] 0.98 [1.11] 0.98 [1.11] 
Decrease 1.05 [1.10]* 1.05 [1.10]* 0.99 [1.10] 0.99 [1.10] 0.99 [1.10] 0.99 [1.10] 0.99 [1.10] 0.99 [1.10] 
   86+ 
Increase 0.70 [1.13]* 0.75 [1.16]* 0.88 [1.17] 0.88 [1.17] 0.88 [1.17] 0.88 [1.17] 0.90 [1.17] 0.89 [1.17] 
Decrease 1.12 [1.13]* 1.11 [1.13]* 0.99 [1.14] 0.98 [1.14] 0.99 [1.14] 0.99 [1.14] 0.99 [1.14] 0.99 [1.14] 
Female 
Increase 1.08 [1.08] 1.06 [1.10] 1.06 [1.10] 1.06 [1.11] 1.06 [1.10] 1.06 [1.10] 1.06 [1.11] 1.06 [1.10] 
Decrease 1.06 [1.09] 1.06 [1.09] 1.03 [1.09] 1.03 [1.10] 1.03 [1.09] 1.03 [1.09] 1.03 [1.10] 1.03 [1.09] 
Race/ethnicity          
   White  1. 1. 1. 1. 1. 1. 1. 1. 
   Black 
Increase 1.50 [1.14]* 1.15 [1.17] 1.14 [1.18] 1.12 [1.18] 1.14 [1.18] 1.14 [1.18] 1.11 [1.18] 1.13 [1.18] 
Decrease 1.18 [1.16] 1.21 [1.16] 1.21 [1.17] 1.18 [1.17] 1.21 [1.17] 1.21 [1.17] 1.22 [1.17] 1.21 [1.17] 
   Hispanic 
Increase 1.63 [1.24]* 1.39 [1.29] 1.29 [1.30] 1.30 [1.30] 1.29 [1.30] 1.30 [1.30] 1.26 [1.31] 1.29 [1.30] 
Decrease 1.23 [1.28] 1.25 [1.28] 1.30 [1.29] 1.28 [1.30] 1.31 [1.29] 1.30 [1.29] 1.32 [1.30] 1.31 [1.29] 
   Asian 
Increase 1.18 [1.29] 1.30 [1.36] 1.16 [1.37] 1.18 [1.38] 1.16 [1.37] 1.17 [1.37] 1.14 [1.38] 1.15 [1.38] 
Decrease 0.87 [1.36] 0.87 [1.36] 0.97 [1.37] 0.97 [1.38] 0.97 [1.37] 0.97 [1.37] 0.98 [1.38] 0.97 [1.37] 
   Other 
Increase 1.21 [1.32] 1.21 [1.39] 1.15 [1.39] 1.15 [1.40] 1.15 [1.39] 1.15 [1.39] 1.11 [1.40] 1.14 [1.39] 
Decrease 1.15 [1.35] 1.15 [1.35] 1.22 [1.36] 1.22 [1.36] 1.22 [1.36] 1.22 [1.36] 1.25 [1.36] 1.23 [1.36] 
Dual eligibility 
Increase 1.12 [1.09] 1.18 [1.11] 1.18 [1.13] 1.19 [1.13] 1.18 [1.13] 1.18 [1.13] 1.14 [1.13] 1.17 [1.13] 
Decrease 0.93 [1.10]* 0.93 [1.10]* 0.80 [1.12] 0.80 [1.12] 0.80 [1.12] 0.80 [1.12] 0.81 [1.12] 0.80 [1.12] 
          
          
          
    
Crude 
estimates 
Crude + 
pre-AMI 
PDC† 
Fully 
adjusted 
model‡ 
Adherence 
change 
conservative§ 
6-week 
follow-upǁ 
Liver 
disease# 
ADD 
change** 
Statin 
intensity†† 
 Patient characteristics   OR [99% CLR] 
Household income          
   ≤$30,000  1. 1. 1. 1. 1. 1. 1. 1. 
   $30,001-60,000 
Increase 0.92 [1.09]* 0.96 [1.10] 0.98 [1.11] 0.99 [1.11] 0.98 [1.11] 0.98 [1.11] 0.99 [1.11] 0.98 [1.11] 
Decrease 0.96 [1.09] 0.95 [1.09] 0.96 [1.10] 0.96 [1.10] 0.96 [1.10] 0.96 [1.10] 0.96 [1.10] 0.96 [1.10] 
   $60,001-100,000 
Increase 0.95 [1.15] 1.03 [1.18] 1.03 [1.18] 1.03 [1.19] 1.03 [1.18] 1.03 [1.18] 1.01 [1.19] 1.03 [1.18] 
Decrease 0.96 [1.16] 0.95 [1.17] 0.96 [1.17] 0.96 [1.17] 0.96 [1.17] 0.96 [1.17] 0.97 [1.17] 0.96 [1.17] 
   $100,001-150,000 
Increase 0.90 [1.37] 1.04 [1.44] 1.05 [1.44] 1.06 [1.45] 1.05 [1.44] 1.05 [1.44] 1.02 [1.45] 1.04 [1.44] 
Decrease 1.01 [1.38] 1.00 [1.38] 1.01 [1.39] 1.01 [1.39] 1.01 [1.39] 1.01 [1.39] 1.03 [1.39] 1.01 [1.39] 
   >$150,000 
Increase 0.92 [1.71] 1.07 [1.87] 1.10 [1.88] 1.11 [1.90] 1.10 [1.88] 1.10 [1.88] 1.07 [1.90] 1.08 [1.88] 
Decrease 0.80 [1.85] 0.80 [1.85] 0.79 [1.85] 0.78 [1.88] 0.80 [1.85] 0.79 [1.85] 0.79 [1.87] 0.80 [1.85] 
Adjusted CCI§§          
   0  1. 1. 1. 1. 1. 1. 1. 1. 
   1-2 
Increase 0.89 [1.11] 0.86 [1.13] 0.88 [1.14] 0.88 [1.14] 0.88 [1.14] 0.88 [1.14] 0.90 [1.14] 0.88 [1.14] 
Decrease 1.08 [1.13] 1.08 [1.13] 1.03 [1.13] 1.03 [1.14] 1.03 [1.13] 1.03 [1.13] 1.01 [1.13] 1.03 [1.13] 
   3-5 
Increase 0.81 [1.12] 0.76 [1.14]* 0.84 [1.16] 0.83 [1.16] 0.84 [1.16] 0.85 [1.16] 0.87 [1.16] 0.85 [1.16] 
Decrease 1.21 [1.13]* 1.21 [1.13]* 1.08 [1.15] 1.07 [1.15] 1.08 [1.15] 1.08 [1.15] 1.04 [1.15] 1.07 [1.15] 
   6-8 
Increase 0.78 [1.18] 0.70 [1.22]* 0.81 [1.24] 0.81 [1.25] 0.81 [1.24] 0.81 [1.25] 0.87 [1.25] 0.82 [1.25] 
Decrease 1.36 [1.19]* 1.36 [1.19]* 1.14 [1.21] 1.14 [1.21] 1.14 [1.21] 1.12 [1.21] 1.08 [1.21] 1.13 [1.21] 
   9 or more 
Increase 0.86 [1.37] 0.66 [1.45] 0.77 [1.47] 0.78 [1.47] 0.77 [1.47] 0.81 [1.48] 0.83 [1.47] 0.78 [1.47] 
Decrease 1.63 [1.35] 1.64 [1.35] 1.39 [1.36] 1.40 [1.37] 1.38 [1.36] 1.42 [1.37] 1.26 [1.37] 1.38 [1.36] 
Baseline comorbidities          
   Prior AMIǁǁ 
Increase 0.86 [1.22] 0.73 [1.26]* 0.92 [1.28] 0.93 [1.29] 0.92 [1.28] 0.92 [1.28] 0.92 [1.29] 0.92 [1.28] 
Decrease 1.17 [1.21]* 1.18 [1.21]* 1.04 [1.23] 1.04 [1.23] 1.04 [1.23] 1.04 [1.23] 1.02 [1.23] 1.04 [1.23] 
   Dementia/      
   Alzheimer's## 
Increase 0.98 [1.14] 0.94 [1.17]* 1.05 [1.18] 1.06 [1.18] 1.05 [1.18] 1.05 [1.18] 1.06 [1.18] 1.05 [1.18] 
Decrease 1.25 [1.14]* 1.26 [1.14]* 1.13 [1.15] 1.13 [1.15] 1.13 [1.15] 1.13 [1.15] 1.13 [1.15] 1.13 [1.15] 
   Depression 
Increase 1.02 [1.12] 0.98 [1.14] 1.02 [1.14] 1.02 [1.15] 1.02 [1.14] 1.02 [1.14] 1.01 [1.15] 1.02 [1.15] 
Decrease 1.18 [1.12] 1.19 [1.12] 1.11 [1.13] 1.11 [1.13] 1.11 [1.13] 1.11 [1.13] 1.12 [1.13] 1.11 [1.13] 
    
Crude 
estimates 
Crude + 
pre-AMI 
PDC† 
Fully 
adjusted 
model‡ 
Adherence 
change 
conservative§ 
6-week 
follow-upǁ 
Liver 
disease# 
ADD 
change** 
Statin 
intensity†† 
 Patient characteristics   OR [99% CLR] 
   CABG 
Increase 1.01 [1.49] 1.11 [1.59] 1.28 [1.61] 1.28 [1.62] 1.27 [1.61] 1.28 [1.61] 1.26 [1.61] 1.29 [1.61] 
Decrease 1.15 [1.50] 1.15 [1.50] 1.13 [1.52] 1.13 [1.53] 1.13 [1.52] 1.13 [1.52] 1.14 [1.53] 1.13 [1.52] 
   PTCA/stent 
Increase 0.87 [1.18] 0.78 [1.21] 0.85 [1.24] 0.84 [1.25] 0.85 [1.24] 0.85 [1.24] 0.88 [1.24] 0.85 [1.24] 
Decrease 1.10 [1.18] 1.11 [1.18] 1.12 [1.20] 1.14 [1.21] 1.12 [1.20] 1.12 [1.20] 1.10 [1.21] 1.11 [1.20] 
   Ischemic heart  
   disease 
Increase 0.78 [1.08]* 0.76 [1.10]* 0.84 [1.11] 0.83 [1.12] 0.84 [1.11] 0.84 [1.11] 0.90 [1.12]* 0.84 [1.12] 
Decrease 1.12 [1.09] 1.13 [1.09] 1.09 [1.11] 1.09 [1.11] 1.10 [1.11] 1.09 [1.11] 1.04 [1.11] 1.08 [1.11] 
   Unstable angina 
Increase 0.84 [1.20] 0.77 [1.24]* 0.89 [1.26] 0.89 [1.27] 0.89 [1.26] 0.89 [1.26] 0.89 [1.27] 0.89 [1.26] 
Decrease 1.10 [1.20] 1.11 [1.20] 1.04 [1.22] 1.05 [1.22] 1.04 [1.22] 1.04 [1.22] 1.04 [1.22] 1.04 [1.22] 
   Lipid abnormalities 
Increase 0.91 [1.13]* 1.03 [1.16] 1.07 [1.17] 1.07 [1.17] 1.07 [1.17] 1.07 [1.17] 1.08 [1.17] 1.07 [1.17] 
Decrease 1.02 [1.15] 1.01 [1.15] 1.00 [1.16] 0.99 [1.16] 1.00 [1.16] 1.00 [1.16] 1.00 [1.16] 0.99 [1.16] 
   Rhabodmyolysis/  
   myopathy 
Increase 1.13 [1.17]* 0.96 [1.20] 1.01 [1.21] 1.01 [1.21] 1.01 [1.21] 1.01 [1.21] 1.01 [1.21] 1.01 [1.21] 
Decrease 1.22 [1.18] 1.24 [1.18] 1.15 [1.18] 1.16 [1.18] 1.15 [1.18] 1.14 [1.18] 1.14 [1.18] 1.14 [1.18] 
Concurrent medications          
   Beta-blocker 
Increase 0.74 [1.08]* 0.88 [1.10]* 0.99 [1.11] 0.99 [1.11] 0.99 [1.11] 0.99 [1.11] 1.01 [1.11] 0.99 [1.11] 
Decrease 0.96 [1.09]* 0.95 [1.09]* 0.88 [1.10] 0.88 [1.10] 0.88 [1.10] 0.88 [1.10] 0.87 [1.10] 0.88 [1.10] 
   ACE inhibitor/ARB 
Increase 0.86 [1.09]* 1.07 [1.10] 1.10 [1.11] 1.10 [1.11] 1.10 [1.11] 1.10 [1.11] 1.11 [1.11] 1.10 [1.11] 
Decrease 0.98 [1.09] 0.98 [1.09] 0.95 [1.10] 0.95 [1.10] 0.95 [1.10] 0.95 [1.10] 0.95 [1.10] 0.95 [1.10] 
Index admission          
   Subendocardial  
   infarction 
Increase 0.79 [1.10]* 0.79 [1.12]* 0.90 [1.13] 0.90 [1.13] 0.90 [1.13] 0.90 [1.13] 0.93 [1.13] 0.91 [1.13] 
Decrease 1.07 [1.12]* 1.07 [1.11]* 0.97 [1.12] 0.97 [1.12] 0.97 [1.12] 0.97 [1.12] 0.96 [1.12] 0.97 [1.12] 
   CABG 
Increase 1.30 [1.17] 1.40 [1.20] 1.34 [1.24] 1.36 [1.24] 1.33 [1.24] 1.34 [1.24] 1.34 [1.24] 1.35 [1.24] 
Decrease 0.88 [1.21]* 0.88 [1.21]* 0.78 [1.24] 0.77 [1.24] 0.79 [1.24] 0.78 [1.24] 0.80 [1.24] 0.78 [1.24] 
   PTCA/stent 
Increase 1.32 [1.08] 1.36 [1.10]* 1.25 [1.13] 1.26 [1.13] 1.24 [1.13] 1.25 [1.13] 1.15 [1.13]* 1.22 [1.13] 
Decrease 0.76 [1.10]* 0.76 [1.10]* 0.82 [1.12] 0.82 [1.12] 0.83 [1.12] 0.82 [1.12] 0.87 [1.12] 0.83 [1.12] 
   Platelet inhibitors 
Increase 1.14 [1.20]* 1.12 [1.24] 1.00 [1.25] 0.99 [1.25] 1.00 [1.25] 1.00 [1.25] 0.97 [1.26] 1.00 [1.25] 
Decrease 0.81 [1.25] 0.81 [1.25] 0.91 [1.26] 0.90 [1.26] 0.91 [1.26] 0.91 [1.26] 0.93 [1.26] 0.91 [1.26] 
          
    
Crude 
estimates 
Crude + 
pre-AMI 
PDC† 
Fully 
adjusted 
model‡ 
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change 
conservative§ 
6-week 
follow-upǁ 
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change** 
Statin 
intensity†† 
 Patient characteristics   OR [99% CLR] 
   Cardiac  
   catheterization 
Increase 1.35 [1.09]* 1.38 [1.10]* 1.09 [1.19] 1.09 [1.19] 1.09 [1.19] 1.09 [1.19] 1.08 [1.19] 1.09 [1.19] 
Decrease 0.81 [1.09]* 0.81 [1.09]* 1.03 [1.19] 1.03 [1.19] 1.03 [1.19] 1.03 [1.19] 1.04 [1.19] 1.03 [1.19] 
   Angiocardiography 
Increase 1.29 [1.08]* 1.34 [1.10]* 1.05 [1.19] 1.06 [1.19] 1.05 [1.19] 1.05 [1.19] 1.04 [1.19] 1.05 [1.19] 
Decrease 0.79 [1.09]* 0.79 [1.09]* 0.90 [1.18] 0.88 [1.18] 0.90 [1.18] 0.90 [1.18] 0.91 [1.19] 0.90 [1.18] 
   Cardiogenic shock 
Increase 1.26 [1.29] 1.37 [1.35]* 1.14 [1.36] 1.14 [1.37] 1.14 [1.36] 1.14 [1.36] 1.13 [1.37] 1.14 [1.36] 
Decrease 1.06 [1.34] 1.05 [1.34] 1.04 [1.35] 1.03 [1.36] 1.04 [1.35] 1.04 [1.35] 1.05 [1.36] 1.04 [1.35] 
   Cardiac  
   dysrhythmias 
Increase 0.90 [1.09] 0.91 [1.11] 0.93 [1.11] 0.93 [1.11] 0.93 [1.11] 0.93 [1.11] 0.94 [1.11] 0.93 [1.11] 
Decrease 1.00 [1.10] 1.00 [1.10] 1.00 [1.10] 1.00 [1.10] 1.00 [1.10] 1.00 [1.10] 0.98 [1.10] 0.99 [1.10] 
   Hypotension 
Increase 1.02 [1.20] 1.07 [1.24] 1.05 [1.24] 1.07 [1.24] 1.05 [1.24] 1.05 [1.24] 1.04 [1.24] 1.04 [1.24] 
Decrease 1.03 [1.21] 1.02 [1.21] 1.01 [1.22] 1.01 [1.22] 1.01 [1.22] 1.01 [1.22] 1.00 [1.22] 1.01 [1.22] 
   Acute renal failure 
Increase 0.95 [1.12] 0.97 [1.14] 1.00 [1.15] 1.01 [1.15] 1.00 [1.15] 1.00 [1.15] 1.00 [1.15] 1.00 [1.15] 
Decrease 1.17 [1.12]* 1.17 [1.12]* 1.05 [1.13] 1.06 [1.13] 1.05 [1.13] 1.05 [1.13] 1.04 [1.13] 1.05 [1.13] 
   Heart failure 
Increase 0.89 [1.09]* 0.90 [1.10]* 1.00 [1.11] 1.01 [1.11] 1.00 [1.11] 1.00 [1.11] 1.02 [1.11] 1.01 [1.11] 
Decrease 1.13 [1.09]* 1.13 [1.09]* 1.02 [1.10] 1.03 [1.10] 1.02 [1.10] 1.02 [1.10] 1.00 [1.10] 1.02 [1.10] 
   Length of stay (days)          
      1-3  1. 1. 1. 1. 1. 1. 1. 1. 
      4-6 
Increase 0.97 [1.10] 0.96 [1.11] 1.00 [1.12] 0.99 [1.12] 1.00 [1.12] 1.00 [1.12] 1.00 [1.12] 1.00 [1.12] 
Decrease 1.12 [1.11]* 1.12 [1.11]* 1.05 [1.11] 1.06 [1.11] 1.05 [1.11] 1.05 [1.11] 1.05 [1.11] 1.05 [1.11] 
      7-11 
Increase 0.98 [1.12] 1.00 [1.14] 1.02 [1.16] 1.02 [1.16] 1.02 [1.16] 1.02 [1.16] 1.03 [1.16] 1.03 [1.16] 
Decrease 1.23 [1.13]* 1.22 [1.13] 1.14 [1.14] 1.15 [1.14] 1.14 [1.14] 1.14 [1.14] 1.13 [1.14] 1.14 [1.14] 
      12+ 
Increase 1.11 [1.17] 1.12 [1.20] 1.08 [1.23] 1.08 [1.23] 1.08 [1.23] 1.08 [1.23] 1.09 [1.23] 1.08 [1.23] 
Decrease 1.34 [1.17] 1.34 [1.17] 1.27 [1.20] 1.28 [1.20] 1.26 [1.20] 1.27 [1.20] 1.23 [1.20] 1.27 [1.20] 
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   Intensive care          
      None  1. 1. 1. 1. 1. 1. 1. 1. 
      Coronary care unit  
      only 
Increase 1.17 [1.12]* 1.16 [1.14]* 1.03 [1.15] 1.03 [1.15] 1.03 [1.15] 1.03 [1.15] 1.02 [1.15] 1.03 [1.15] 
Decrease 0.98 [1.13] 0.98 [1.13] 1.03 [1.13] 1.03 [1.14] 1.03 [1.13] 1.03 [1.13] 1.04 [1.14] 1.03 [1.13] 
      Intensive care unit  
      only 
Increase 1.10 [1.11]* 1.10 [1.13]* 1.01 [1.13] 1.01 [1.13] 1.01 [1.13] 1.01 [1.13] 1.01 [1.13] 1.01 [1.13] 
Decrease 1.04 [1.11] 1.04 [1.11] 1.05 [1.12] 1.05 [1.12] 1.06 [1.12] 1.05 [1.12] 1.05 [1.12] 1.05 [1.12] 
      Both 
Increase 1.25 [1.15]* 1.26 [1.18]* 1.03 [1.20] 1.02 [1.20] 1.03 [1.20] 1.03 [1.20] 1.01 [1.20] 1.02 [1.20] 
Decrease 1.01 [1.17] 1.01 [1.17] 1.04 [1.18] 1.04 [1.18] 1.04 [1.18] 1.04 [1.18] 1.04 [1.19] 1.04 [1.18] 
   Cardiologist consult 
Increase 1.12 [1.13] 1.15 [1.15]* 1.04 [1.16] 1.04 [1.16] 1.03 [1.16] 1.04 [1.16] 1.02 [1.16] 1.03 [1.16] 
Decrease 0.91 [1.13] 0.91 [1.13] 0.95 [1.14] 0.94 [1.14] 0.96 [1.14] 0.95 [1.14] 0.96 [1.14] 0.95 [1.14] 
30-day follow-up          
   None  1. 1. 1. 1. 1. 1. 1. 1. 
   Primary care provider  
   only*** 
Increase 0.96 [1.14]* 1.04 [1.16] 1.08 [1.16] 1.10 [1.17] 1.08 [1.19] 1.08 [1.16] 1.06 [1.17] 1.07 [1.16] 
Decrease 1.01 [1.14] 1.00 [1.14] 0.97 [1.14] 0.97 [1.15] 0.97 [1.16] 0.97 [1.14] 0.98 [1.15] 0.97 [1.14] 
   Cardiologist only 
Increase 1.05 [1.15]* 1.20 [1.17] 1.15 [1.18] 1.18 [1.19] 1.16 [1.21] 1.15 [1.18] 1.10 [1.18] 1.14 [1.18] 
Decrease 0.86 [1.16] 0.85 [1.16] 0.91 [1.17] 0.91 [1.17] 0.86 [1.19] 0.91 [1.17] 0.94 [1.17] 0.92 [1.17] 
   Both 
Increase 1.03 [1.13]* 1.22 [1.15] 1.21 [1.16] 1.25 [1.16] 1.24 [1.18] 1.21 [1.16] 1.17 [1.16] 1.20 [1.16] 
Decrease 0.95 [1.14] 0.94 [1.14] 0.95 [1.14] 0.95 [1.14] 0.92 [1.16] 0.95 [1.14] 0.97 [1.14] 0.96 [1.14] 
Mild liver diseaseǁǁ 
Increase      1.00 [1.43]   
Decrease      1.19 [1.36]   
Moderate/sever liver 
diseaseǁǁ 
Increase      0.47 [3.42]   
Decrease      1.10 [2.49]   
Change in simvastatin-
equivalent ADD** 
Increase       1.01 [1.00]  
Decrease       0.99 [1.00]  
          
          
          
    
Crude 
estimates 
Crude + 
pre-AMI 
PDC† 
Fully 
adjusted 
model‡ 
Adherence 
change 
conservative§ 
6-week 
follow-upǁ 
Liver 
disease# 
ADD 
change** 
Statin 
intensity†† 
 Patient characteristics   OR [99% CLR] 
Pre-AMI statin 
intensity†† 
 
        
   Low 
Increase        1.08 [1.22] 
Decrease        0.79 [1.25] 
   Moderate         1. 
   High 
Increase        0.80 [1.17] 
Decrease        1.32 [1.18] 
Post-AMI statin 
intensity†† 
 
        
   Low 
Increase        0.79 [1.26] 
Decrease        1.32 [1.27] 
   Moderate         1. 
   High 
Increase        1.33 [1.15] 
Decrease               0.77 [1.17] 
All eight models are using the three-level multinomial logistic regression comparing decrease in adherence to no change and comparing increase in adherence 
to no change. *Point estimate does not fall within the 99% confidence interval for the original full model (Model 1 from Table 2 in the main manuscript). 
†Estimates are only adjusted for pre-AMI adherence. ‡Fully adjusted model (Model 1 from Table 2 in the main manuscript). §This model required categorical 
changes in statin adherence to be at least a 10% absolute difference from pre- to post-AMI PDC (e.g. a pre-AMI PDC of 78% to post-AMI PDC of 84% would 
not be considered an adherence increase in this sensitivity analysis). ǁThe period for post-AMI follow-up with clinicians was extended to 42 days (6 weeks). 
#CCI measures of liver disease were added as separate variables to the model and the CCI score was further adjusted by not including mild and 
moderate/severe liver disease. **Weighted average of the simvastatin-equivalent average daily dose in the post-AMI period minus the weighted average of the 
simvastatin-equivalent average daily dose in the pre-AMI period. Dose equivalency calculations were made as follows: fluvastatin, pravastatin, and lovastatin 
doses in mg were divided by 4, 2, and 2, respectively; atorvastatin, rosuvastatin, and pitavastatin doses in mg were multiplied by 2, 4, and 10, respectively. 
††Statin intensity was measured using the LAST statin prescription claim filled BEFORE the index AMI hospitalization and using the FIRST claim filled 
AFTER the index hospitalization discharge. Statin intensity was measured according to the 2013 American College of Cardiology/ American Heart Association 
Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. ‡‡Odds ratio for a 10% higher pre-AMI adherence 
(e.g. 50% compared to 40%). §§CCI score does not include counts for AMI and dementia; in the liver disease sensitivity analysis, it also does not include those 
measures. ǁǁCCI definition. ##Medicare Chronic Condition Data Warehouse definition. ***Primary care physician, physician assistant, or nurse practitioner. 
Abbreviations: AMI=acute myocardial infarction; PDC=proportion of days covered; ADD=average daily dose; OR=odds ratio; CLR=confidence limit ratio 
(upper 99% confidence limit divided by the lower limit); CCI=Charlson Comorbidity Index; CABG=Coronary artery bypass surgery; PTCA=percutaneous 
transluminal coronary angioplasty; ACE=angiotensin-converting enzyme; ARB=angiotensin II receptor blocker. 
Table S7. Fully adjusted model and sensitivity analyses with restricted cohort eligibility for the 
three-level multinomial regression model predicting statin adherence change after an AMI. 
    
Fully 
adjusted 
model* 
Prevalent 
statin users† 
Post-AMI 
6-month 
survival‡ 
No AMI 6-
month post-
AMI§ 
  N=113,296 N=101,905 N=101,015 N=104,572 
 Patient characteristics   OR [99% CLR] 
Pre-AMI PDC (10%)ǁ 
Increase 0.67 [1.01] 0.68 [1.02] 0.67 [1.02] 0.67 [1.02] 
Decrease 1.04 [1.02] 1.04 [1.02] 1.05 [1.02] 1.04 [1.02] 
Age      
   66-75  1. 1. 1. 1. 
   76-85 
Increase 0.97 [1.11] 0.97 [1.11] 0.97 [1.12] 0.98 [1.11] 
Decrease 0.99 [1.10] 0.99 [1.11] 0.99 [1.11] 0.99 [1.11] 
   86+ 
Increase 0.88 [1.17] 0.87 [1.18] 0.89 [1.18] 0.89 [1.18] 
Decrease 0.99 [1.14] 1.01 [1.16] 0.98 [1.16] 0.99 [1.15] 
Female 
Increase 1.06 [1.10] 1.06 [1.11] 1.08 [1.11] 1.07 [1.11] 
Decrease 1.03 [1.09] 1.03 [1.10] 1.03 [1.10] 1.03 [1.10] 
Race/ethnicity      
   White  1. 1. 1. 1. 
   Black 
Increase 1.14 [1.18] 1.15 [1.19] 1.13 [1.19] 1.12 [1.19] 
Decrease 1.21 [1.17] 1.19 [1.19] 1.22 [1.19] 1.22 [1.18] 
   Hispanic 
Increase 1.29 [1.30] 1.30 [1.32] 1.30 [1.32] 1.32 [1.32] 
Decrease 1.30 [1.29] 1.27 [1.33] 1.36 [1.32] 1.37 [1.31] 
   Asian 
Increase 1.16 [1.37] 1.16 [1.39] 1.14 [1.40] 1.14 [1.39] 
Decrease 0.97 [1.37] 0.99 [1.40] 0.98 [1.40] 0.97 [1.40] 
   Other 
Increase 1.15 [1.39] 1.16 [1.42] 1.12 [1.42] 1.13 [1.41] 
Decrease 1.22 [1.36] 1.19 [1.40] 1.22 [1.38] 1.25 [1.37] 
   Dual eligibility 
Increase 1.18 [1.13] 1.18 [1.13] 1.20 [1.14] 1.20 [1.13] 
Decrease 0.80 [1.12] 0.81 [1.13] 0.80 [1.13] 0.80 [1.13] 
Household income      
   ≤$30,000  1. 1. 1. 1. 
   $30,001-60,000 
Increase 0.98 [1.11] 1.00 [1.11] 0.98 [1.11] 0.99 [1.11] 
Decrease 0.96 [1.10] 0.96 [1.11] 0.96 [1.10] 0.96 [1.10] 
   $60,001-100,000 
Increase 1.03 [1.18] 1.05 [1.19] 1.03 [1.20] 1.04 [1.19] 
Decrease 0.96 [1.17] 0.96 [1.18] 0.96 [1.18] 0.97 [1.17] 
   $100,001-150,000 
Increase 1.05 [1.44] 1.05 [1.47] 1.07 [1.47] 1.03 [1.46] 
Decrease 1.01 [1.39] 1.03 [1.42] 1.00 [1.42] 0.98 [1.40] 
   >$150,000 
Increase 1.10 [1.88] 1.15 [1.94] 1.27 [1.93] 1.08 [1.93] 
Decrease 0.79 [1.85] 0.81 [1.96] 0.82 [1.95] 0.82 [1.89] 
      
      
      
      
    
Fully 
adjusted 
model* 
Prevalent 
statin users† 
Post-AMI 
6-month 
survival‡ 
No AMI 6-
month post-
AMI§ 
  N=113,296 N=101,905 N=101,015 N=104,572 
 Patient characteristics   OR [99% CLR] 
Adjusted CCI#      
   0  1. 1. 1. 1. 
   1-2 
Increase 0.88 [1.14] 0.89 [1.14] 0.88 [1.14] 0.88 [1.14] 
Decrease 1.03 [1.13] 1.02 [1.15] 1.03 [1.14] 1.03 [1.14] 
   3-5 
Increase 0.84 [1.16] 0.87 [1.16] 0.85 [1.16] 0.85 [1.16] 
Decrease 1.08 [1.15] 1.07 [1.16] 1.09 [1.16] 1.08 [1.15] 
   6-8 
Increase 0.81 [1.24] 0.84 [1.26] 0.79 [1.27] 0.81 [1.26] 
Decrease 1.14 [1.21] 1.15 [1.23] 1.12 [1.23] 1.11 [1.22] 
   9 or more 
Increase 0.77 [1.47] 0.77 [1.49] 0.82 [1.59] 0.75 [1.50] 
Decrease 1.39 [1.36] 1.45 [1.40] 1.21 [1.48] 1.44 [1.38] 
Baseline comorbidities      
   Prior AMI** 
Increase 0.92 [1.28] 0.91 [1.31] 0.96 [1.32] 0.90 [1.32] 
Decrease 1.04 [1.23] 0.99 [1.26] 1.07 [1.26] 1.01 [1.26] 
   Dementia/Alzheimer's†† 
Increase 1.05 [1.18] 1.02 [1.19] 1.05 [1.20] 1.05 [1.19] 
Decrease 1.13 [1.15] 1.17 [1.16] 1.13 [1.17] 1.12 [1.16] 
   Depression 
Increase 1.02 [1.14] 1.03 [1.15] 1.00 [1.16] 1.01 [1.15] 
Decrease 1.11 [1.13] 1.13 [1.14] 1.12 [1.14] 1.12 [1.13] 
   CABG 
Increase 1.28 [1.61] 1.35 [1.69] 1.30 [1.63] 1.29 [1.64] 
Decrease 1.13 [1.52] 1.15 [1.65] 1.16 [1.54] 1.14 [1.54] 
   PTCA/stent 
Increase 0.85 [1.24] 0.86 [1.26] 0.84 [1.26] 0.85 [1.26] 
Decrease 1.12 [1.20] 1.12 [1.23] 1.12 [1.22] 1.14 [1.22] 
   Ischemic heart disease 
Increase 0.84 [1.11] 0.85 [1.12] 0.83 [1.12] 0.84 [1.12] 
Decrease 1.09 [1.11] 1.07 [1.12] 1.12 [1.11] 1.10 [1.11] 
   Unstable angina 
Increase 0.89 [1.26] 0.89 [1.28] 0.89 [1.28] 0.89 [1.28] 
Decrease 1.04 [1.22] 0.99 [1.25] 1.02 [1.24] 1.04 [1.23] 
Lipid abnormalities 
Increase 1.07 [1.17] 1.06 [1.18] 1.06 [1.18] 1.06 [1.18] 
Decrease 1.00 [1.16] 1.03 [1.17] 0.99 [1.17] 0.98 [1.16] 
   Rhabodmyolysis/  
   myopathy 
Increase 1.01 [1.21] 1.01 [1.22] 0.98 [1.22] 1.03 [1.22] 
Decrease 1.15 [1.18] 1.15 [1.20] 1.15 [1.20] 1.16 [1.19] 
Concurrent medications      
   Beta-blocker 
Increase 0.99 [1.11] 1.00 [1.11] 0.98 [1.12] 0.98 [1.11] 
Decrease 0.88 [1.10] 0.91 [1.11] 0.87 [1.11] 0.88 [1.10] 
   ACE inhibitor/ARB 
Increase 1.10 [1.11] 1.10 [1.11] 1.09 [1.11] 1.10 [1.11] 
Decrease 0.95 [1.10] 0.96 [1.11] 0.95 [1.10] 0.97 [1.10] 
Index admission      
   Subendocardial  
   infarction 
Increase 0.90 [1.13] 0.91 [1.13] 0.90 [1.13] 0.92 [1.13] 
Decrease 0.97 [1.12] 0.96 [1.13] 0.97 [1.13] 0.97 [1.13] 
      
    
Fully 
adjusted 
model* 
Prevalent 
statin users† 
Post-AMI 
6-month 
survival‡ 
No AMI 6-
month post-
AMI§ 
  N=113,296 N=101,905 N=101,015 N=104,572 
 Patient characteristics   OR [99% CLR] 
   CABG 
Increase 1.34 [1.24] 1.36 [1.25] 1.37 [1.25] 1.36 [1.24] 
Decrease 0.78 [1.24] 0.77 [1.26] 0.78 [1.24] 0.78 [1.24] 
   PTCA/stent 
Increase 1.25 [1.13] 1.23 [1.13] 1.26 [1.13] 1.26 [1.13] 
Decrease 0.82 [1.12] 0.80 [1.13] 0.83 [1.13] 0.83 [1.12] 
   Platelet inhibitors 
Increase 1.00 [1.25] 0.99 [1.27] 0.99 [1.26] 1.01 [1.26] 
Decrease 0.91 [1.26] 0.92 [1.29] 0.92 [1.27] 0.92 [1.27] 
   Cardiac catheterization 
Increase 1.09 [1.19] 1.09 [1.20] 1.08 [1.20] 1.08 [1.20] 
Decrease 1.03 [1.19] 1.03 [1.21] 1.03 [1.19] 1.03 [1.19] 
   Angiocardiography 
Increase 1.05 [1.19] 1.04 [1.20] 1.03 [1.20] 1.06 [1.19] 
Decrease 0.90 [1.18] 0.90 [1.20] 0.90 [1.19] 0.90 [1.19] 
   Cardiogenic shock 
Increase 1.14 [1.36] 1.14 [1.39] 1.18 [1.40] 1.16 [1.38] 
Decrease 1.04 [1.35] 1.00 [1.40] 1.03 [1.39] 1.07 [1.36] 
   Cardiac dysrhythmias 
Increase 0.93 [1.11] 0.93 [1.11] 0.93 [1.12] 0.93 [1.11] 
Decrease 1.00 [1.10] 1.01 [1.11] 1.00 [1.10] 1.00 [1.10] 
   Hypotension 
Increase 1.05 [1.24] 1.07 [1.25] 1.04 [1.25] 1.04 [1.25] 
Decrease 1.01 [1.22] 1.03 [1.24] 0.99 [1.23] 0.98 [1.23] 
   Acute renal failure 
Increase 1.00 [1.15] 0.99 [1.16] 0.98 [1.16] 1.00 [1.16] 
Decrease 1.05 [1.13] 1.07 [1.14] 1.05 [1.14] 1.05 [1.13] 
   Heart failure 
Increase 1.00 [1.11] 1.00 [1.11] 1.02 [1.12] 1.01 [1.11] 
Decrease 1.02 [1.10] 1.03 [1.11] 1.03 [1.11] 1.02 [1.10] 
   Length of stay (days)      
      1-3  1. 1. 1. 1. 
      4-6 
Increase 1.00 [1.12] 0.99 [1.13] 1.00 [1.13] 1.02 [1.13] 
Decrease 1.05 [1.11] 1.06 [1.12] 1.05 [1.12] 1.06 [1.12] 
      7-11 
Increase 1.02 [1.16] 1.00 [1.17] 1.01 [1.17] 1.02 [1.17] 
Decrease 1.14 [1.14] 1.15 [1.15] 1.15 [1.15] 1.16 [1.14] 
      12+ 
Increase 1.08 [1.23] 1.09 [1.24] 1.06 [1.25] 1.07 [1.24] 
Decrease 1.27 [1.20] 1.31 [1.22] 1.32 [1.22] 1.28 [1.21] 
   Intensive care      
      None  1. 1. 1. 1. 
      Coronary care unit  
      only 
Increase 1.03 [1.15] 1.03 [1.16] 1.04 [1.16] 1.05 [1.15] 
Decrease 1.03 [1.13] 1.03 [1.15] 1.03 [1.14] 1.02 [1.14] 
      Intensive care unit  
      only 
Increase 1.01 [1.13] 1.01 [1.14] 1.00 [1.14] 1.01 [1.14] 
Decrease 1.05 [1.12] 1.06 [1.13] 1.05 [1.12] 1.05 [1.12] 
      Both 
Increase 1.03 [1.20] 1.04 [1.21] 1.05 [1.21] 1.03 [1.21] 
Decrease 1.04 [1.18] 1.03 [1.20] 1.05 [1.20] 1.05 [1.19] 
   Cardiologist consult 
Increase 1.04 [1.16] 1.03 [1.17] 1.01 [1.17] 1.05 [1.17] 
Decrease 0.95 [1.14] 0.93 [1.15] 0.94 [1.15] 0.95 [1.14] 
    
Fully 
adjusted 
model* 
Prevalent 
statin users† 
Post-AMI 
6-month 
survival‡ 
No AMI 6-
month post-
AMI§ 
  N=113,296 N=101,905 N=101,015 N=104,572 
 Patient characteristics   OR [99% CLR] 
30-day follow-up      
   None  1. 1. 1. 1. 
   Primary care provider  
   only‡‡ 
Increase 1.08 [1.16] 1.05 [1.17] 1.11 [1.18] 1.07 [1.17] 
Decrease 0.97 [1.14] 0.98 [1.16] 0.95 [1.16] 0.97 [1.15] 
   Cardiologist only 
Increase 1.15 [1.18] 1.14 [1.19] 1.19 [1.19] 1.16 [1.19] 
Decrease 0.91 [1.17] 0.91 [1.19] 0.92 [1.18] 0.91 [1.17] 
   Both 
Increase 1.21 [1.16] 1.21 [1.17] 1.25 [1.17] 1.21 [1.17] 
Decrease 0.95 [1.14] 0.96 [1.16] 0.95 [1.15] 0.95 [1.15] 
All four models are using the three-level multinomial logistic regression comparing decrease in adherence to 
no change and comparing increase in adherence to no change. No point estimates fell outside of the 99% 
confidence interval for the original full model (Model 1 from Table 2 in the main manuscript). *Fully adjusted 
model (Model 1 from Table 2 in the main manuscript). †Patients who were first identified as statin users in our 
data within the 6 months prior to index AMI were excluded (i.e. only prevalent statin users were included). 
‡Patients must have survived 6 months post-AMI discharge to be included in model. §Patients with another 
AMI within 6 months after their index AMI hospital discharge were excluded from model. ǁOdds ratio for a 
10% higher pre-AMI adherence (e.g. 50% compared to 40%). #CCI score does not include counts for AMI 
and dementia. **CCI definition. ††Medicare Chronic Condition Data Warehouse definition. ‡‡Primary care 
physician, physician assistant, or nurse practitioner. Abbreviations: AMI=acute myocardial infarction; 
PDC=proportion of days covered; OR=odds ratio; CLR=confidence limit ratio (upper 99% confidence limit 
divided by the lower limit); CCI=Charlson Comorbidity Index; CABG=Coronary artery bypass surgery; 
PTCA=percutaneous transluminal coronary angioplasty; ACE=angiotensin-converting enzyme; 
ARB=angiotensin II receptor blocker. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S8. Three-level multinomial regression models predicting change from 1-year pre-AMI 
statin adherence to 1-year post-AMI statin adherence (N=112,780). 
  3-Level Multinomial Logistic Regression† 
 OR (99% CI) 
Patient Characteristics Decrease Increase 
Pre-AMI PDC (10%)§ 1.00 (0.99, 1.01)* 0.61 (0.61, 0.62)* 
Age   
   66-75 1. 1. 
   76-85 0.99 (0.94, 1.03) 0.98 (0.93, 1.04) 
   86+ 0.98 (0.92, 1.04) 0.89 (0.82, 0.97) 
Female 1.03 (0.98, 1.07) 1.05 (1.00, 1.11) 
Race/ethnicity   
   White 1. 1. 
   Black 1.17 (1.09, 1.26) 1.05 (0.96, 1.15) 
   Hispanic 1.26 (1.12, 1.42) 1.27 (1.11, 1.46) 
   Asian 0.97 (0.84, 1.12) 1.09 (0.92, 1.29) 
   Other 1.19 (1.04, 1.38) 1.15 (0.97, 1.37) 
Dual eligibility 0.77 (0.73, 0.81) 1.18 (1.11, 1.26) 
Household income#   
   ≤$30,000 1. 1. 
   $30,001-60,000 0.96 (0.92, 1.00) 0.99 (0.94, 1.05) 
   $60,001-100,000 0.95 (0.89, 1.02) 1.05 (0.96, 1.15) 
   $100,001-150,000 0.98 (0.84, 1.14) 1.10 (0.90, 1.33) 
   >$150,000 0.91 (0.69, 1.19) 1.07 (0.76, 1.51) 
Adjusted CCI**   
   0 1. 1. 
   1-2 1.07 (1.01, 1.13) 0.92 (0.86, 0.98) 
   3-5 1.13 (1.06, 1.20) 0.87 (0.80, 0.94) 
   6-8 1.18 (1.08, 1.29) 0.86 (0.77, 0.97) 
   9 or more 1.56 (1.35, 1.80) 0.87 (0.71, 1.07) 
Baseline comorbidities   
   Prior AMI†† 1.03 (0.94, 1.14) 1.00 (0.87, 1.14) 
   Dementia/Alz‡‡ 1.18 (1.11, 1.26) 1.16 (1.06, 1.26)* 
   Depression 1.10 (1.05, 1.17) 1.03 (0.96, 1.10) 
   CABG 0.95 (0.78, 1.16) 1.28 (0.99, 1.64) 
   PTCA/stent 1.16 (1.07, 1.26) 0.84 (0.75, 0.95) 
   Ischemic heart disease 1.10 (1.05, 1.16) 0.81 (0.76, 0.86) 
   Unstable angina 1.05 (0.96, 1.15) 0.90 (0.79, 1.02) 
   Lipid abnormalities 0.98 (0.92, 1.05) 1.09 (1.00, 1.19) 
   Rhabdo/myopathy 1.09 (1.01, 1.17) 1.00 (0.90, 1.10) 
   
  3-Level Multinomial Logistic Regression† 
 OR (99% CI) 
Patient Characteristics Decrease Increase 
Concurrent medications   
   Beta-blocker 0.89 (0.86, 0.93) 0.98 (0.93, 1.04) 
   ACE inhibitor/ARB 0.97 (0.93, 1.01) 1.08 (1.02, 1.14) 
Index admission   
   Subend infarction§§ 0.98 (0.93, 1.03) 0.89 (0.83, 0.95) 
   CABG 0.75 (0.68, 0.82) 1.37 (1.22, 1.53) 
   PTCA/stent 0.87 (0.82, 0.91) 1.24 (1.16, 1.32) 
   Platelet inhibitors 0.97 (0.88, 1.08) 0.90 (0.80, 1.02) 
   Cardiac catheterization 1.05 (0.98, 1.14) 1.03 (0.94, 1.13) 
   Angiocardiography 0.87 (0.80, 0.94) 1.09 (0.99, 1.19) 
   Cardiogenic shock 0.99 (0.86, 1.13) 1.10 (0.93, 1.29) 
   Cardiac dysrhythmias 1.03 (0.99, 1.08) 0.98 (0.93, 1.04) 
   Hypotension 0.99 (0.91, 1.08) 1.00 (0.89, 1.12) 
   Acute renal failure 1.09 (1.03, 1.15) 1.02 (0.95, 1.10) 
   Heart failure 1.01 (0.97, 1.06) 1.02 (0.96, 1.07) 
   Length of stay (days)   
      1-3 1. 1. 
      4-6 1.04 (0.99, 1.09) 1.02 (0.96, 1.08) 
      7-11 1.10 (1.03, 1.16) 1.06 (0.98, 1.14) 
      12+ 1.19 (1.09, 1.29) 1.14 (1.02, 1.27) 
   Intensive care   
      None 1. 1. 
      CCU only 1.03 (0.97, 1.09) 1.03 (0.96, 1.11) 
      ICU only 1.06 (1.00, 1.11) 1.03 (0.96, 1.10) 
      Both 1.04 (0.97, 1.13) 1.05 (0.96, 1.16) 
   Cardiologist consult 0.95 (0.90, 1.01) 1.00 (0.93, 1.08) 
30-day follow-up   
   None 1. 1. 
   PCP onlyǁǁ 0.98 (0.92, 1.04) 1.12 (1.03, 1.21) 
   Cardiologist only 0.90 (0.84, 0.97) 1.16 (1.06, 1.27) 
   Both 0.94 (0.88, 0.99) 1.27 (1.17, 1.37) 
*Point estimate does not fall within the 99% confidence interval for the original full model (Model 1 from 
Table 2 in the main manuscript). †Three-level multinomial logistic regression comparing decrease in 
adherence to no change and comparing increase in adherence to no change. §Odds ratio for a 10% higher pre-
AMI adherence (e.g. 50% compared to 40%). ǁEnrolled in Medicare and Medicaid. #Median household 
income of US Census block groups for individuals aged 65 and older. **CCI score does not include counts for 
AMI and dementia. ††CCI definition. ‡‡Medicare Chronic Condition Data Warehouse definition. §§Diagnosis 
code for subendocardial infarction, compared to a transmural infarction. ǁǁPrimary care physician, physician 
assistant, or nurse practitioner. Abbreviations: AMI=acute myocardial infarction; OR=odds ratio; 
CI=confidence interval; PDC=proportion of days covered; CCI=Charlson Comorbidity Index; 
Alz=Alzheimer’s disease; CABG=Coronary artery bypass surgery; PTCA=percutaneous transluminal 
coronary angioplasty; Rhabdo=rhabdomyolysis; ACE=angiotensin-converting enzyme; ARB=angiotensin II 
receptor blocker; subend=subendocardial; CCU=coronary care unit; ICU=intensive care unit; PCP=primary 
care provider. 
 
 
Table S9. Three-level multinomial regression model predicting statin adherence change after an 
AMI using a likelihood function conditional on the pre-AMI adherence category.† 
  3-Level Multinomial Logistic Regression‡ 
 OR (99% CI) 
Patient Characteristics Decrease Increase 
Age   
   66-75 1. 1. 
   76-85 0.98 (0.93, 1.02) 1.00 (0.95, 1.06) 
   86+ 0.97 (0.90, 1.03) 0.97 (0.89, 1.06)* 
Female 1.04 (0.99, 1.08) 1.02 (0.97, 1.08) 
Race/ethnicity   
   White 1. 1. 
   Black 1.29 (1.19, 1.40) 0.94 (0.86, 1.02)* 
   Hispanic 1.36 (1.19, 1.55) 1.09 (0.94, 1.25)* 
   Asian 0.98 (0.84, 1.15) 1.16 (0.96, 1.40) 
   Other 1.24 (1.06, 1.44) 1.02 (0.85, 1.23) 
Dual eligibility§ 0.77 (0.73, 0.82) 1.31 (1.23, 1.40)* 
Household incomeǁ   
   ≤$30,000 1. 1. 
   $30,001-60,000 0.95 (0.91, 1.00) 0.98 (0.93, 1.04) 
   $60,001-100,000 0.95 (0.88, 1.03) 1.03 (0.94, 1.13) 
   $100,001-150,000 0.99 (0.84, 1.17) 1.05 (0.86, 1.30) 
   >$150,000 0.77 (0.56, 1.05) 1.06 (0.74, 1.52) 
Adjusted CCI#   
   0 1. 1. 
   1-2 1.04 (0.98, 1.11) 0.86 (0.80, 0.93) 
   3-5 1.10 (1.03, 1.18) 0.83 (0.76, 0.90) 
   6-8 1.17 (1.06, 1.29) 0.79 (0.70, 0.89) 
   9 or more 1.47 (1.26, 1.72) 0.72 (0.59, 0.88) 
Baseline comorbidities   
   Prior AMI** 1.14 (1.06, 1.22) 1.01 (0.93, 1.10) 
   Dementia/Alzheimer’s†† 1.07 (0.97, 1.19) 0.95 (0.83, 1.08) 
   Depression 1.12 (1.05, 1.19) 0.99 (0.92, 1.06) 
   CABG 1.11 (0.90, 1.37) 1.28 (0.98, 1.67) 
   PTCA/stent 1.14 (1.04, 1.26) 0.82 (0.73, 0.92) 
   Ischemic heart disease 1.11 (1.06, 1.17) 0.77 (0.73, 0.82)* 
   Unstable angina 1.05 (0.96, 1.16) 0.88 (0.78, 0.99) 
   Lipid abnormalities 0.97 (0.90, 1.05) 1.00 (0.92, 1.09) 
   Rhabdomyolysis/myopathy 1.18 (1.08, 1.28) 0.98 (0.89, 1.09) 
Concurrent medications   
   Beta-blocker 0.85 (0.81, 0.89) 0.99 (0.94, 1.05) 
   ACE inhibitor/ARB 0.92 (0.88, 0.96) 1.07 (1.02, 1.13) 
Index admission   
   Subendocardial infarction‡‡ 0.97 (0.92, 1.03) 0.91 (0.85, 0.97) 
   CABG 0.77 (0.69, 0.86) 1.50 (1.32, 1.69)* 
   PTCA/stent 0.82 (0.77, 0.86) 1.33 (1.25, 1.42)* 
  3-Level Multinomial Logistic Regression‡ 
 OR (99% CI) 
Patient Characteristics Decrease Increase 
   Platelet inhibitors 0.91 (0.81, 1.02) 0.99 (0.87, 1.12) 
   Cardiac catheterization 1.04 (0.95, 1.13) 1.10 (0.99, 1.21) 
   Angiocardiography 0.89 (0.81, 0.96) 1.05 (0.96, 1.16) 
   Cardiogenic shock 1.03 (0.89, 1.20) 1.10 (0.92, 1.32) 
   Cardiac dysrhythmias 1.00 (0.96, 1.05) 0.95 (0.90, 1.01) 
   Hypotension 1.00 (0.91, 1.11) 1.04 (0.92, 1.17) 
   Acute renal failure 1.05 (0.99, 1.12) 0.99 (0.92, 1.07) 
   Heart failure 1.02 (0.98, 1.07) 1.02 (0.96, 1.08) 
   Length of stay (days)   
      1-3 1. 1. 
      4-6 1.06 (1.00, 1.11) 1.01 (0.95, 1.07) 
      7-11 1.14 (1.07, 1.22) 1.04 (0.96, 1.13) 
      12+ 1.27 (1.16, 1.39) 1.06 (0.95, 1.19) 
   Intensive care   
      None 1. 1. 
      Coronary care unit only 1.03 (0.97, 1.10) 1.04 (0.97, 1.13) 
      Intensive care unit only 1.06 (1.00, 1.12) 1.02 (0.96, 1.09) 
      Both 1.05 (0.96, 1.14) 1.00 (0.91, 1.11) 
   Cardiologist consult 0.95 (0.89, 1.01) 1.04 (0.96, 1.13) 
30-day follow-up   
   None 1. 1. 
   Primary care provider only§§ 0.95 (0.89, 1.02) 1.12 (1.04, 1.21) 
   Cardiologist only 0.88 (0.82, 0.96) 1.22 (1.11, 1.33) 
   Both 0.92 (0.86, 0.98) 1.32 (1.22, 1.43)* 
*Point estimate does not fall within the 99% confidence interval for the original full model (Model 
1 from Table 2 in the main manuscript). †Using PROC NLMIXED in SAS, the likelihood function 
was defined as conditional on the pre-AMI adherence category. Patients who were moderately non-
adherent (pre-AMI PDC 40-79.9%) were compared to the whole population on the likelihood of 
having no change, decreased, or increased adherence. Patients who were severely non-adherent 
(pre-AMI PDC <40%) were compared to patients who were severely non-adherent or moderately 
non-adherent on the likelihood of having no change or increased adherence. Patients who were 
adherent (pre-AMI PDC ≥80%) were compared to patients who were adherent or moderately non-
adherent on the likelihood of having no change or decreased adherence. ‡Three-level multinomial 
logistic regression comparing decrease in adherence to no change and comparing increase in 
adherence to no change. §Enrolled in Medicare and Medicaid. ǁMedian household income of US 
Census block groups for individuals aged 65 and older. #CCI score does not include counts for 
AMI and dementia. **CCI definition. ††Medicare Chronic Condition Data Warehouse definition. 
‡‡Diagnosis code for subendocardial infarction, compared to a transmural infarction. §§Primary 
care physician, physician assistant, or nurse practitioner. Abbreviations: AMI=acute myocardial 
infarction; OR=odds ratio; CI=confidence interval; PDC=proportion of days covered; 
CCI=Charlson Comorbidity Index; CABG=Coronary artery bypass surgery; PTCA=percutaneous 
transluminal coronary angioplasty; ACE=angiotensin-converting enzyme; ARB=angiotensin II 
receptor blocker. 
 
Table S10. Linear regression model predicting statin adherence change after an AMI. 
Patient Characteristics Mean Change in PDC (99% CI)* 
Intercept† -2.93 (-4.16, -1.70) 
Pre-AMI PDC‡ -0.50 (-0.51, -0.50) 
Age  
   66-75 0. 
   76-85 0.13 (-0.33, 0.59) 
   86+ -0.05 (-0.71, 0.61) 
Female -0.04 (-0.47, 0.40) 
Race/ethnicity  
   White 0. 
   Black -1.36 (-2.13, -0.59) 
   Hispanic -0.38 (-1.63, 0.87) 
   Asian 0.92 (-0.53, 2.37) 
   Other -0.64 (-2.15, 0.87) 
Dual eligibility§ 3.65 (3.12, 4.18) 
Household incomeǁ  
   ≤$30,000 0. 
   $30,001-60,000 0.31 (-0.14, 0.76) 
   $60,001-100,000 0.71 (-0.04, 1.46) 
   $100,001-150,000 0.65 (-0.95, 2.25) 
   >$150,000 2.20 (-0.61, 5.01) 
Adjusted CCI#  
   0 0. 
   1-2 -1.20 (-1.78, -0.62) 
   3-5 -2.03 (-2.68, -1.38) 
   6-8 -2.68 (-3.63, -1.74) 
   9 or more -5.49 (-7.12, -3.86) 
Baseline comorbidities  
   Prior AMI** -0.88 (-1.93, 0.17) 
   Dementia/Alzheimer’s†† -1.37 (-2.08, -0.66) 
   Depression -0.69 (-1.29, -0.10) 
   CABG 0.59 (-1.52, 2.69) 
   PTCA/stent -2.50 (-3.42, -1.57) 
   Ischemic heart disease -2.67 (-3.15, -2.18) 
   Unstable angina -1.04 (-2.02, -0.05) 
   Lipid abnormalities 0.29 (-0.41, 0.98) 
   Rhabdo/myopathy -1.34 (-2.18, -0.50) 
Concurrent medications  
   Beta-blocker 0.70 (0.24, 1.16) 
   ACE inhibitor/ARB 0.77 (0.32, 1.21) 
Patient Characteristics Mean Change in PDC (99% CI)* 
Index admission  
   Subendocardial infarction‡‡ -0.61 (-1.15, -0.07) 
   CABG 5.02 (4.04, 6.00) 
   PTCA/stent 3.65 (3.12, 4.19) 
   Platelet inhibitors 0.79 (-0.24, 1.81) 
   Cardiac catheterization 0.49 (-0.31, 1.28) 
   Angiocardiography 1.31 (0.53, 2.09) 
   Cardiogenic shock 0.89 (-0.56, 2.33) 
   Cardiac dysrhythmias -0.39 (-0.84, 0.06) 
   Hypotension -0.01 (-0.96, 0.94) 
   Acute renal failure -0.34 (-0.95, 0.26) 
   Heart failure -0.10 (-0.55, 0.35) 
   Length of stay (days)  
      1-3 0. 
      4-6 -0.39 (-0.89, 0.11) 
      7-11 -1.17 (-1.81, -0.54) 
      12+ -1.96 (-2.87, -1.06) 
   Intensive care  
      None 0. 
      Coronary care unit only 0.18 (-0.42, 0.79) 
      Intensive care unit only -0.23 (-0.76, 0.31) 
      Both 0.06 (-0.74, 0.87) 
   Cardiologist consult 0.92 (0.29, 1.56) 
30-day follow-up  
   None 0. 
   Primary care provider only§§ 0.92 (0.26, 1.58) 
   Cardiologist only 2.37 (1.63, 3.11) 
   Both 2.44 (1.79, 3.08) 
*Linear regression model predicting adherence change as a continuous outcome (post-AMI PDC minus pre-AMI 
PDC). Estimates can be interpreted as follows: an estimate of 2.44 means that the patient characteristic is 
associated with a 2.44% increase in PDC (e.g. 70.00% to 72.44%) compared to the reference category after an 
AMI, holding all other patient characteristics constant; an estimate of -1.96 means the patient characteristic is 
associated with a 1.96% decrease in PDC compared to the reference category after an AMI. †Predicted change 
in adherence for patients with a pre-AMI PDC of 80% and all other variables set to the reference category. 
‡Predicted change in statin adherence associated with a 1% increase in pre-AMI PDC (e.g. a patient with a pre-
AMI PDC of 75% would be predicted to have a 0.50% decrease in statin PDC after an AMI compared to a 
patient with 74% PDC pre-AMI). §Enrolled in Medicare and Medicaid. ǁMedian household income of US 
Census block groups for individuals aged 65 and older. #CCI score does not include counts for AMI and 
dementia. **CCI definition. ††Medicare Chronic Condition Data Warehouse definition. ‡‡Diagnosis code for 
subendocardial infarction, compared to a transmural infarction. §§Primary care physician, physician assistant, or 
nurse practitioner. Abbreviations: AMI=acute myocardial infarction; PDC=proportion of days covered; 
CI=confidence interval; CCI=Charlson Comorbidity Index; CABG=Coronary artery bypass surgery; 
PTCA=percutaneous transluminal coronary angioplasty; ACE=angiotensin-converting enzyme; 
ARB=angiotensin II receptor blocker. 
 
Figure S1. Sensitivity analysis showing distribution of 1-year post-AMI adherence stratified by 
1-year pre-AMI adherence 
 
 
 
AMI=acute myocardial infarction; PDC=proportion of days covered. 
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